VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 15 (1-10 julio / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas Covid.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

COVID-19: ¿Y qué sí sabemos de las vacunas y variantes?

2 jul. La COVID-19 se ha combatido con vacunas bivalentes y monovalentes, y las nuevas dosis deberán desarrollarse contra las subvariantes de ómicron, al ser las dominantes, refieren las agencias sanitarias.

Las dosis bivalentes "incluyen un componente de la cepa del virus original (...) y de la variante ómicron", indica la Administración de Drogas y Alimentos de Estados Unidos (FDA).

Las monovalentes "tienen un sólo componente o uno que corresponde a la cepa original del virus".

En EU, la enfermedad sigue siendo una preocupación para las personas mayores de 65 años y las personas con sistemas inmunológicos débiles.

Por lo anterior, la FDA y los Centros para el Control y la Prevención de Enfermedades (CDC) ofrecen una segunda vacuna de refuerzo bivalente.

Los CDC recomiendan tener una dosis bivalente a todas las personas mayores de seis años, independientemente de si completaron previamente su serie primaria (monovalente). Además, permiten una dosis adicional bivalente para los adultos de 65 años o más, y dosis adicionales para los inmunodeprimidos.

Las monovalentes, contra el vector original, ya no se recomiendan en EU.

En marzo, un estudio de los CDC mostró que las bivalentes son eficaces contra la variante XBB.1.5.

Sin embargo, según estudios de la FDA, la eficacia de la vacuna bivalente COVID-19 contra los sublinajes de ómicron parece disminuir con el tiempo.

En el futuro, la OMS, la Agencia Europea de Medicamentos (EMA) y el Centro Europeo para la Prevención y Control de Enfermedades (ECDC) recomiendan "una vacuna monovalente adaptada al linaje XBB.1 de ómicron el próximo otoño". Pfizer/BioNtech, Moderna y Novavax ya están desarrollando versiones de sus respectivas inmunizaciones contra el XBB.1.5 y otras subvariantes del COVID-19.

Fuente: El Universal. Disponible en https://cutt.ly/ZwiBmWkT

La primera vacuna contra la fiebre chikungunya obtiene una respuesta serológica del 98.9 %, manteniéndola funcional hasta seis meses después de la vacunación en el 96 % de los participantes.

3 jul. El biológico fue desarrollado por el laboratorio francés Valvena, quien ya solicitó su aprobación y registro a las autoridades regulatorias de los EE. UU., Canadá y Europa.

Un equipo de investigadores del laboratorio francés especializado en vacunas, Valvena, desarrolló una vacuna de virus vivos atenuados VLA1553 de una sola aplicación contra el virus chikungunya, la que en un reciente estudio clínico de fase 3, demostró inducir una eficaz respuesta inmune protectora contra el virus.

Los resultados del estudio se publicaron el pasado 12 de junio en la revista The Lancet, con el título: *"Safety*

and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial", y en ellos consta que la tasa de respuesta serológica alcanzada por la vacuna, fue del 98.9 % a los 28 días después de una sola inoculación, mostrando un perfil de inmunogenicidad similar en adultos jóvenes como mayores, y mínimos efectos secundarios. Otro dato relevante, es que el 96% de los participantes mantuvo la respuesta serológica seis meses después de la vacunación.

El estudio clínico de fase 3, fue doble ciego, multicéntrico, aleatorizado, y se realizó en 43 sitios de ensayo de vacunas profesionales en los EE. UU. Los 4 mil 129 participantes elegidos eran voluntarios sanos mayores de 18 años. Previamente se habían excluido a 1972 personas que tenían antecedentes de infección por el virus chikungunya, o artritis, o artralgia inmunomediada o crónica, defecto conocido o sospechado del sistema inmunitario, que hubieran recibido cualquier vacuna inactivada dentro de las 2 semanas previas a la vacunación con VLA1553, o cualquier vacuna viva recibida dentro de las 4 semanas. antes de la vacunación con VLA1553. Los participantes fueron aleatorizados para recibir VLA1553 o placebo.

Valvena presentó la solicitud de aprobación a las autoridades regulatorias de los EE. UU., y la Unión Europea, de las que se espera una respuesta positiva.

Fuente: Código F. Disponible en https://cutt.ly/HwiBOkBq

Mexico highlights use of Cuban Abdala vaccine in pediatric age group



3 jul. The Cuban vaccine Abdala received the approval of the Federal Commission for Protection against Health Risks (Cofepris), the Mexican regulatory authority, to be used in pediatric patients from 5 years of age onwards, Granma newspaper reported today.

The drug, the first anti-COVID-19 vaccine produced in Latin America and the Caribbean, developed by the Center for Genetic Engineering and Biotechnology (CIGB) will be able to be used in pediatric ages, as reported on Twitter by the Business Group of the Biotechnological and Pharmaceutical Industries.

On the same social media, Roberto Morales Ojeda, Secretary of Organization of the Central Committee of the Communist Party of Cuba, shared the news and congratulated all those who in one way or another have contributed to achieve this result, which represents another achievement for Cuban biotechnology.

Since last May, the New Molecules Committee (CMN) of Cofepris issued a favorable opinion on the vaccine as part of the process to obtain authorization for emergency use issued by the Health Authorization Commission of Cofepris, once the information submitted has been evaluated.

With its three-dose scheme, Abdala demonstrated 92.28 % efficacy in the prevention of symptomatic disease caused by the SARS-CoV-2 virus.

Fuente: ACN Cuban News Agency. Disponible en https://cutt.ly/EwiNjpT7

15 vacunas que han cambiado la historia de la humanidad

3 jul. Desde los inicios de 2020, el año que trajo consigo la pandemia que ha transformado nuestro mundo, la ciencia ha trabajado a contrarreloj en la investigación de la vacuna contra la COVID-19. Tras unos meses de caída de su incidencia en gran parte gracias a la vacunación a nivel global de más de 8 470 millones de dosis, a finales de 2021 hoy la pandemia ha retomado la volatilidad de sus cifras a causa de la última variante ómicron, menos agresiva en sus síntomas pero fuertemente contagiosa. Pero los primeros análisis de esta nueva variante siguen apuntando a que las vacunas están marcando la diferencia, y no es la primera vez en la historia que las inoculaciones son el arma sanitaria clave para luchar contra una epidemia.

Desde que fue declarada pandemia global por la Organización Mundial de la Salud, las cifras del coronavirus han continuado su ascenso, transformando la realidad de todos los países hasta el último detalle de nuestro día a día. Desde la llegada de la COVID-19, los casos rondan los 14 millones en España y los 770 millones a nivel global. Aunque obtener la cifra real de fallecidos es difícil, en España superan los 120 000 y a nivel mundial son casi 7 millones, según datos del Ministerio de Sanidad y de *Our World in data*. Al analizar los datos de esta pandemia a través de un prisma global, las cifras aún están lejos de sus competidores más letales de la historia, pero debido a la globalización actual y las circunstancias en las que se ha desarrollado la COVID-19, estos dos años han dado un gran protagonismo en nuestros días a la importancia vital de las vacunas.

El siglo pasado, la humanidad aún convivía de manera habitual con diversas epidemias amenazaban al mundo entero con brotes de sarampión, viruela, tifus o fiebre amarilla. Hasta que llegó la vacunación. Pero, ¿cuál fue su origen y cuáles han sido las vacunas más importantes a lo largo de la historia?

A lo largo de los últimos dos siglos, su uso ha salvado miles de millones de vidas en todo el planeta y ha frenado enfermedades devastadoras en todo el mundo. Sin embargo, la amnesia histórica nos hace olvidar con facilidad cómo era el mundo antes de las vacunas y son muchos los que alzan la voz contra las inoculaciones, por motivos religiosos, políticos o creencias distorsionadas. De forma paradójica, las vacunas nos salvan de enfermedades y a su vez hacen que, al desaparecer la amenaza, olvidemos las enfermedades de las que nos han salvado.

La inoculación china

Para dar con el origen de esta técnica científica debemos remontarnos a la lucha contra la viruela en China. “Varios relatos del siglo XVI describen la inoculación contra la viruela y señalan que, a fines del siglo XVII, el emperador K'ang Hsi, que había sobrevivido a la viruela cuando era niño, hizo que sus hijos fueran vacunados”, afirman los datos del Colegio de Médicos de Filadelfia.

Los médicos desarrollaron una técnica llamada variolización, que consistía en pulverizar la piel de una persona con síntomas para insuflarlo por las vías respiratorias de personas sanas con el objetivo de inmunizarlas. Esta técnica se extendió por el mundo hasta la llegada del descubrimiento de las propias vacunas. “Es difícil precisar cuándo comenzó la práctica, ya que algunas fuentes afirman que se remontan al 200 a. C.”.

Vacuna de la viruela (1796)

“La medicina china y su cultura ancestral parecen tener los antecedentes más remotos de los intentos por prevenir o curar el azote epidemiológico de esa época: la viruela”, afirma el estudio *Los orígenes de la*

vacuna, publicado en la revista médica Elsevier. “Estos conocimientos empíricos llegaron al Asia Central y Europa, y algunos granjeros hicieron observaciones de la utilidad de la inoculación o variolización sin llegar a documentar sus ensayos en la comunidad científica”.

No fue hasta 1798 cuando el cirujano Edward Anthony Jenner (1749-1823), conocido como el padre de la vacunación, revolucionó la lucha contra la viruela. El planteamiento de Jenner fue que si una persona se infecta con una carga viral inofensiva, adquiere inmunidad a un agente patógeno similar. En aquel momento utilizó el virus de la viruela de las vacas para proteger de la viruela humana.

El 1 de julio de 1796, Jenner infectó a un niño de ocho años con el virus de la viruela, pocas semanas después de haberle administrado el virus de la viruela vacuna, demostrando su inmunidad ante un virus que durante siglos había sido una gran amenaza.

“La viruela era una enfermedad altamente prevalente, causante de un gran problema epidemiológico, distribuida en casi todo el mundo, que no distinguía edades ni clases sociales, y además causaba alta mortalidad – del 30 al 60 por ciento en los no vacunados - y producía secuelas significativas”.

Entre las muchos afectados por esta enfermedad se encuentran faraones de Egipto, según certifican sus momias, Isabel I de Inglaterra, músicos clásicos como Mozart y Beethoven, y presidentes de los Estados Unidos como Lincoln y Washington o el rey Luis I de España.

Vacuna de la rabia (1885)

A finales del siglo XIX, el bacteriólogo francés Louis Pasteur revolucionó de nuevo el mundo de la medicina descubriendo la vacuna contra la rabia a partir de una cepa atenuada del virus. Esta enfermedad zoonótica viral tiene una letalidad cercana al 100 % y está causada a través de un virus que infecta animales e insectos y ataca el sistema nervioso central causando una encefalitis aguda.

Difundida a lo largo de la historia por todo el planeta este virus ataca a mamíferos domésticos y salvajes incluyendo al ser humano se encuentra en la saliva los animales infectados y se inocula a los humanos cuando estos provocan alguna lesión por mordedura o hay contacto con las secreciones salivales.

La Organización Mundial de la Salud (OMS) maneja datos que afirman que en algunas regiones esta enfermedad aún es un problema de salud pública como Asia o África donde causa más de 55 000 muertes al año la mayoría menores de 15 años de edad.

Vacuna contra el tétanos (1890) y fiebre amarilla (1937)

En 1890, Emil von Behring – llamado el salvador de los soldados y los niños - descubrió, en estudios en animales, que era posible producir inmunidad contra el tétanos, una enfermedad del sistema nervioso, al inyectar dosis graduadas de suero de otro animal portador de la enfermedad.

Al empezar la I Guerra Mundial, los soldados empezaron a recibir pequeñas dosis del suero, ya que no había sido probado en humanos previamente. En 1914 consiguieron que la Administración lo distribuyera en mayores cantidades para evitar un mayor número de muertes. Por sus estudios en este campo y el de la difteria, Behring fue galardonado con el primer premio Nobel en Medicina.

Por su parte, la fiebre amarilla ha sido la causa de epidemias y pandemias devastadoras a lo largo de la historia, como la que afectó a Barcelona en 1821. La enfermedad era endémica de África hasta que el tránsito de los esclavos africanos en el siglo XV la distribuyó al continente americano, donde la falta de

inmunidad hacia ella provocó una pandemia altamente letal que afectó a los colonos europeos en África y América.

La OMS incluyó en la lista de los medicamentos permitidos la vacuna contra la fiebre amarilla en el año 1938, tras más de cinco siglos causando epidemias mortales en el planeta. A día de hoy, aún se registran cada año 200 000 casos y cerca de 30 000 muertos.

Esta vacuna nació gracias al científico sudafricano Max Thyler, que siguiendo la línea de una investigación anterior de la cepa atenuada, logró vacunar a más de un millón de de personas. Por ello, Theiler fue galardonado con el premio Nobel de Medicina en 1951.

Después de que el británico Almroth Edward White desarrollara la vacuna del tifus, a finales del siglo XIX, la década de 1920 vio nacer las vacunas contra la tuberculosis, la difteria, el tétanos y la tosferina.

Los descubrimientos de Hilleman

En abril de 1957, una misteriosa enfermedad avanzaba por Hong Kong. El virólogo estadounidense Maurice Hilleman, que había nacido en agosto de 1919, en plena pandemia de gripe española, reconoció la amenaza y comenzó a trabajar en una vacuna que frenó la enfermedad cuando llegó a Estados Unidos, salvando millones de vidas.

Hilleman estudió en el Instituto Walter Reed de Investigación Médica Militar, en Washington D.C., los brotes de gripe y las enfermedades respiratorias. Allí demostró que los virus de la gripe sufrían mutaciones que les permiten eludir los anticuerpos desarrollados previamente, lo que explicaba por qué una sola vacuna no protegía de por vida, como ocurría con las de la viruela o la polio.

"En 1957 lo pasamos por alto. El ejército lo pasó por alto y la OMS también", dijo Hilleman más adelante en una entrevista.

En total, el virus mató a 1,1 millones de personas en todo el mundo. Cuando llegó a Estados Unidos, el virólogo ya había creado 40 millones de dosis. "Es la única vez que se ha evitado una pandemia con una vacuna", recordó Hilleman.

Polio, sarampión, rubeola y paperas (década de 1960)

Aunque se estima que la polio ha afectado las poblaciones humanas durante miles de años, a finales del siglo XIX, la enfermedad alcanzó proporciones epidémicas que aún afectan gravemente a Asia y, hasta hace poco, a África, donde fue erradicada en agosto de 2020.

En España se usó, entre los años 1959 y 1963, la vacuna de polio inactivada, que se administraba gratuitamente a quienes no tenían recursos, aunque las coberturas fueron bajas, ya que la cantidad de vacunas disponibles era escasa. En 1965 se inició una nueva campaña masiva y al mismo tiempo se añadió la vacunación frente a la difteria, el tétanos y la tosferina. El éxito de estas intervenciones determinó que, a partir de este momento, se realizaran de manera continua.

Otras tres infecciones que han causado y siguen causando miles de muertes son el sarampión, la rubeola y las paperas. Ya en el siglo XX, durante la década de 1960, Hilleman creó en 1967 una vacuna para las paperas, en el 69 para la rubeola y dos años más tarde una vacuna combinada que proporcionaría inmunidad para los tres virus, conocida comúnmente como triple vírica.

Los investigadores de la farmacéutica Merck, bajo la dirección de Maurice Hilleman, detectaron un virus de

simio en las células de riñón de mono que se utilizan para cultivar poliovirus para la vacuna contra la polio de Merck. Hilleman demostró más tarde que el virus de los simios, SV40, causaba tumores en hámsteres.

Merck finalmente retiró del mercado su vacuna contra la polio. En 1963, los programas de detección del gobierno comenzaron a buscar virus de simio en las vacunas contra el poliovirus. Hilleman también estuvo tras las vacunas, en la década de 1970, de la varicela, el neumococo y la meningitis.

Posteriormente, aunque hubo una epidemia de un tipo de gripe muy parecida a la gripe de 1918, no tuvo demasiada expansión. La siguiente vacuna con mayor impacto mundial, por tanto, es la del coronavirus. Su brutal impacto inmediato en el mundo entero debido a la globalización, llevó a todos los laboratorios internacionales a tratar de encontrar la vacuna lo antes posible.



A día de hoy, aún existen muchas enfermedades infecciosas que causan millones de muertes al año, sobre todo afecciones como el VIH y la tuberculosis que aún no tienen vacuna. Otra de las grandes preocupaciones sanitarias globales, la malaria, ha vivido en octubre de 2021 un "momento histórico" con la aprobación de la primera vacuna contra esta enfermedad. Además, según alerta el Programa de las Naciones Unidas para el Medio Ambiente (PNUMA), el cambio climático y la pérdida de biodiversidad son factores que multiplican el riesgo de sufrir nuevas pandemias en el futuro.

Fuente: NATIONAL GEOGRAPHIC. Disponible en https://www.nationalgeographic.es/ciencia/2021/12/vacunas-que-han-cambiado-la-historia-de-la-humidad

Triple Protection: Flu, COVID, RSV Vaccines To Help Prevent Resurgence Of Respiratory Illnesses This Fall

Jul 5. In an effort to safeguard public health, health officials in the United States are strongly advocating for the administration of flu, COVID-19 and respiratory syncytial virus (RSV) vaccines this fall. This strategic approach aims to thwart the resurgence of respiratory illnesses, preventing a potential "tripledemic" similar to the previous winter. Insurance-covered individuals can access these vaccines free of charge.

Dr. Ofer Levy, an advisor to the Food and Drug Administration (FDA) and director of the precision vaccines program at Boston Children's Hospital, lauds the plethora of vaccination options available, referring to it as an "embarrassment of riches," New York Times reported.

Given the altered seasonal patterns caused by pandemic restrictions, the exact timing and severity of the coronavirus, flu and RSV resurgence remain uncertain. Last winter, the flu peaked earlier in December than usual, potentially resulting in a higher number of deaths, estimated at around 58,000. COVID-19 maintained a steady rate of infections and fatalities throughout the season, with its peak occurring in January.

While RSV may be less familiar to the general public, experts now recognize it as a significant threat, particularly affecting older adults, immunocompromised individuals and young children.

Dr. Helen Chu, an immunologist and physician at the University of Washington, recognized the severity of RSV, which can cause illness comparable to the flu, especially among older adults.

Predicting the future patterns of respiratory viruses remains challenging. While scientists anticipate a return to

pre-pandemic patterns eventually, Dr. Chu cautioned that the next two years may bring unpredictability, per the New York Times.

Health experts unanimously recommended receiving both the flu and COVID-19 vaccines this fall. While the flu vaccine is crucial for everyone aged six months and older, it holds particular importance for adults aged 65 and above, children under five and individuals with weakened immune systems.

Updated COVID-19 shots targeting the Omicron variant (XBB.1.5) are expected from Pfizer, Moderna, and Novavax. Full recommendations will be available following FDA authorization and CDC review.

Rather than focusing on boosters, federal health officials now promote the concept of a single annual immunization with the latest version of the COVID-19 vaccine. They compared the vaccine to a seatbelt, stressing the importance of ongoing protection.

The new RSV vaccine is currently approved for Americans aged 60 and older, with the CDC recommending consultation with doctors for individuals in this age group.

Although risks increase with age, even those without pre-existing conditions can become severely ill from any of the three viruses. Therefore, it is advisable to get vaccinated early enough in the fall to build immunity against these pathogens.

To streamline the process, most Americans should consider receiving the flu and COVID-19 shots simultaneously. Older adults in poor health, such as those with heart or lung disease or on home oxygen, are encouraged to receive all three vaccines together, preferably before the season begins.

Fuente: Medical Daily. Disponible en https://www.medicaldaily.com/triple-protection-flu-covid-rsv-vaccines-help-prevent-resurgence-respiratory-illnesses-this-470425

Países africanos recibirán primera vacuna del mundo contra la malaria

6 jul. Doce países de África recibirán 18 millones de dosis de la primera vacuna del mundo contra la malaria para combatir la enfermedad que se cobra la vida de casi medio millón de niños al año.

El fármaco RTS, S/AS01 se suministrará durante los próximos dos años. Entre los países que se beneficiarán se encuentran Benín, Burkina Faso, Burundi, Camerún, República Democrática del Congo, Liberia, Níger, Sierra Leona y Uganda, donde las tasas de incidencia y mortalidad por malaria son mayores, según un comunicado difundido por el Fondo de las Naciones Unidas para la Infancia (Unicef).

“Esta vacuna tiene el potencial de tener un gran impacto en la lucha contra la malaria, y cuando se implementa ampliamente junto con otras intervenciones puede prevenir decenas de miles de muertes cada año”, dijo el responsable de la alianza para vacunas Gavi, Thabani Maphosa. Otros 16 países africanos también han solicitado el fármaco.

El uso del RTS,S/AS01 empezó en 2019, en el marco de un programa piloto lanzado en Ghana, Kenia y Malaui. Más de 1.7 millones de niños ya han sido vacunados con el fármaco en esos países.

Los resultados obtenidos en el programa permitieron clasificar a la vacuna como “segura y eficaz” en la reducción de muertes por malaria.

La malaria es una enfermedad infecciosa causada por parásitos trasmitidos a los humanos a través de la picadura de mosquitos del género Anopheles.

Los síntomas incluyen fiebre (que puede ser periódica), escalofríos, rigidez, sudoración, diarrea, dolor abdominal, dificultad respiratoria, confusión, convulsiones, anemia hemolítica y anomalías renales.

Fuente: Cubadebate. Disponible en http://www.cubadebate.cu/noticias/2023/07/06/paises-africanos-recibiran-primera-vacuna-del-mundo-contra-la-malaria/

EMA-endorsed statement targets COVID-19 vaccine misinformation

jul 6. In an age where COVID-19 vaccine misinformation is rife, the International Coalition of Medicines Regulatory Authorities (ICMRA) issued a statement tackling the exaggerations of side effect severity and frequency.

The 5 July statement, which was swiftly endorsed by the European Medicines Agency (EMA), points to overwhelming evidence demonstrating a good safety profile across all age groups.

There have so far been more than 13 billion vaccine doses given worldwide. ICMRA says the vast majority of side effects due to COVID-19 vaccines are mild and temporary. Any serious side effects identified by safety monitoring systems, such as myocarditis and blood clots, are very rare – meaning they occur in less than one in 10,000 people.

The statement pointed towards false and misleading information being spread, especially on social media, that exaggerates the frequency and severity of side effects.

The statement read: “As for all medicines, reports of medical events after COVID-19 vaccination (suspected side effects) are collected and continuously evaluated by the authorities. These evaluations show that in most cases the medical events were not caused by the vaccine.”

In May 2023, the World Health Organisation (WHO) declared an end to the COVID-19 public health emergency. Although extensive nationwide vaccination programmes have wound down, vaccines protecting against a wide range of SARS-CoV-2 strains are still available. In recent months, regulatory agencies have updated recommendations based on emerging strains, encouraging companies such as Moderna to develop updated vaccines that can be used as boosters.

ICMRA also went on to say that misinformation has likely led to more deaths than adverse effects of the vaccines. There is no evidence to support the notion that COVID-19 vaccines contributed to excess mortality

during the pandemic. Instead, a wealth of evidence indicates that vaccines saved millions of lives.

The statement added: “False information on COVID-19 vaccine safety is dangerous and can contribute to the growing problem of vaccine hesitancy. It can also affect trust in other life-saving routine childhood vaccinations.”

Fuente: Pharmaceutical Technology. Disponible en https://www.pharmaceutical-technology.com/news/ema-endorsed-statement-targets-covid-19-vaccine-misinformation/#catfish

Australia’s drug regulator received two hoax reports of children dying from Covid vaccines

Jul 9. Australia’s drug regulator received two reports of child deaths after vaccination against Covid-19 that turned out to be hoaxes.

Therapeutic Goods Administration documents on fatal adverse events in children and adolescents after a Covid-19 vaccination published under freedom of information show that a report was made to the body in January 2022 that a seven-year-old boy had died from “an adverse event following immunisation” with an unspecified brand of Covid vaccine.

A separate report made in March the same year claimed a six-year-old boy had died after receiving the Pfizer vaccine.

Both reports were found to be hoaxes, the document says. The TGA report details nine deaths in children ranging from five to 17 years old after Covid vaccination in Australia between September 2021 and March 2023 but emphasises that it is not certain the deaths had been caused by vaccination.

“The symptom may be related to the underlying illness or to other factors,” the report says. “There might be no relationship between the adverse event and the medicine – it may be a coincidence that the adverse event occurred when the medicine was taken.”

Covid vaccines are safe for children, with vaccine safety data from AusVaxSafety showing that children aged five to 11 are reporting fewer short-term vaccine side-effects than those reported by older Australians.

Vaccination is recommended for everyone aged five years and over. It is also recommended for children aged six months to under five years who are severely immunocompromised or have disability, as well as those who have complex health conditions that increase their risk of severe Covid.

A TGA spokesperson said the regulator was “confident that hoax reports are not affecting our ability to closely monitor the safety of medicines and vaccines”.

“Anyone at any time can report an adverse event to the TGA, even if the chance of it being caused by the medicine or vaccine is unlikely,” the spokesperson said.

“While this approach ensures that there is no restriction to adverse event reporting, and that we gather as much safety information as possible, it does mean that occasionally intentionally false or hoax reports are made. However, we consider that it would be a very small number, with most reporters doing the right thing.”

Fatal vaccine reports are verified by the TGA with health services, state and territory health departments, forensic services, public health units and coroners to ensure the information is followed up.

Fuente: The Guardian. Disponible en https://www.theguardian.com/australia-news/2023/jul/10/tga-covid-vaccine-child-death-hoax

Novavax's COVID-19 vaccine granted full marketing authorisation in EU

Jul 10. Novavax has announced that its COVID-19 vaccine, Nuvaxovid, has been granted full marketing authorisation in the EU.

The vaccine is now fully authorised for use as a primary series in individuals aged 12 and older for COVID-19 prevention and as a booster dose in adults aged 18 and older, the company said.

Novavax's protein-based vaccine, which was originally granted a conditional marketing authorisation in the EU for these indications, contains the SARS-CoV-2 spike protein and Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralising antibodies.

The European Commission's latest decision follows a recommendation by the European Medicines Agency's human medicines committee earlier this year and is supported by positive results from the phase 3 PREVENT trial that evaluated the safety, immunogenicity, and efficacy of Nuvaxovid.

John Jacobs, president and chief executive officer of Novavax, said: "This marketing authorisation establishes the foundation for all future regulatory approvals for updated versions of our COVID-19 vaccine, a necessity to ensure we can quickly get our vaccine to individuals in the EU."

Jacob's added: "In addition to the EU, we are preparing to file for full approval in the US as well as other markets and are committed to ensuring protein-based options are available worldwide."

The authorisation comes less than a month after a US Food and Drug Administration (FDA) panel of advisors has unanimously recommended that updated COVID-19 vaccines being developed for the US autumn vaccination campaign target one of the currently circulating XBB variants.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to zero in favour of the monovalent XBB-lineage vaccines and generally agreed that vaccines targeting the XBB.1.5 subvariant would be preferred.

Novavax, Pfizer/BioNTech, and Moderna are already developing versions of their respective vaccines targeting XBB.1.5 and other currently circulating subvariants.

Selecting XBB.1.5 as the target strain would be particularly beneficial for Novavax, as the biotech's protein-based vaccine takes longer to manufacture than its rivals' mRNA vaccines.

In a statement published after the advisory meeting, Jacobs, said: "[The company] expects to be ready for the commercial delivery of a protein-based monovalent XBB COVID-19 vaccine this autumn in line with [the] VRBPAC recommendation."

Fuente: PMLiVE. Disponible en https://www.pmlive.com/pharma_news/novavaxs_covid-19_vaccine_granted_full_marketing_authorisation_in_eu_1494368

RSV vaccine for older adults approved by UK medicines regulator

Jul 10. The UK's medicines regulator has approved the first vaccine against respiratory syncytial virus (RSV) in older adults.

The virus typically causes cold-like symptoms, but is a leading cause of pneumonia in infants and elderly people, with infections in older adults accounting for about 8,000 deaths, 14,000 hospitalisations and 175,000 GP appointments in the UK each year – more than influenza during a typical winter season.

People with underlying medical conditions, such as diabetes and chronic heart or lung disease, are at greatest risk of severe illness. There are no specific treatments for RSV but those with severe infections may be supported with supplemental oxygen, intravenous fluids, or mechanical ventilation until they get better.

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the vaccine, Arexvy, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults 60 years and older – the first time an RSV vaccine for older adults has been authorised for use in the UK.

A study of 24,966 older adults published in the New England Journal of Medicine in February suggested vaccine efficacy against LRTD was 82.6%, while efficacy against serious disease was 94.1%.

The vaccine was generally well tolerated, with mild to moderate injection site pain, fatigue, muscle and joint aches or pain and headache the most commonly reported side events. The rate of serious adverse effects was similar between those receiving the vaccine or a placebo jab.

The vaccine, produced by GlaxoSmithKline, has already been approved for use in the US and Europe. Further adult RSV vaccines from Moderna and Pfizer are expected to be considered in the coming months.

On 22 June, the Joint Committee on Vaccination and Immunisation (JCVI), which advises UK governments on matters of immunisation, issued a short statement to the Department of Health and Social Care advising that a cost-effective RSV immunisation programme should be developed for infants and older adults.

The JCVI cited modelling by the London School of Hygiene & Tropical Medicine and other academic groups suggesting that a vaccination programme for older adults could be cost-effective.

It currently favours a "one-off vaccination campaign targeting several age cohorts and then a routine programme for those turning 75 years old", the statement said.

A final statement to inform a policy decision about potential RSV immunisation programmes is expected later this summer.

Prof Sir Andrew Pollard, the chair of the JCVI said: "There is a substantial burden of RSV infection in older adults, which contributes to the seasonal winter pressures for the NHS.

"Clinical trials of several products have shown that vaccination can boost immunity and reduce the risk of infection and hospitalisation with the potential to improve population health."

The JCVI is closely monitoring the development of products to protect newborns and infants against RSV, which is the leading cause of hospitalisation in infants worldwide.

Maternal vaccines, which are designed to be given during pregnancy, are now in late-stage clinical trials, while an antibody-based drug called nirsevimab was licensed by the MHRA in November 2022. It is designed to protect babies during their first RSV season, when they are most vulnerable.

Fuente: The Guardian. Disponible en https://www.theguardian.com/society/2023/jul/10/rsv-vaccine-respiratory-syncytial-virus-older-adults-approved-uk-medicines-regulator

EU vaccine transparency: a shot in the dark

Jul 10. One of the European Parliament's key tasks is budgetary control: scrutinising if billions of taxpayers' money are spent in a proper and useful way. But in case of the EU's response to the Covid-19 pandemic and the tens of billions of euros the EU spends on purchasing vaccines from powerful pharmaceutical companies like Pfizer, it has renounced this task.

From recent letters seen by Corporate Europe Observatory, it seems the European Parliament president Roberta Metsola prevented her own institution doing its work by denying MEPs access to crucial information.

This adds to the culture of secrecy installed by EU Commission president Ursula von der Leyen and her refusal to be transparent and be held accountable by the special COVI-committee that was created on 10 March last year.

COVI's mission was to examine the EU's response to the pandemic and identifying lessons to be drawn to be better prepared for future health crises. During the COVI meetings, the debate on how to improve transparency was omnipresent. On (Wednesday) 12 July the European Parliament plenary will vote on the final COVI-report.

Foot-dragging

From the very start, COVI asked the European Commission to get full access for its members to the non-redacted contracts the EU signed with Big Pharma. The European Commission dragged its feet over the whole year.

The COVI-coordinators on 13 July last year requested an extended access to the contracts, also for MEP assistants, political advisors and the secretariat.

Metsola forwarded this request in a letter dated 16 September to von der Leyen. What happened after is not entirely clear.

But what is clear from correspondence is that Metsola did in the following months not follow the demands of COVI but struck a deal with von der Leyen instead.

On 15 November 2022, COVI-chair Kathleen van Brempt (S&D) again wrote a letter to the 'Classified Information Unit' of the European Parliament requesting access to the negotiation files and the contracts, which the parliament had already received in autumn 2021. The non-redacted vaccine contracts were then accessible in a secret reading room (with confidentiality restrictions) for a selected and unofficial group of MEPs: the Vaccine Contact Group.

Pfizer decides?

The arm-wrestling on democratic needed access to crucial information continued till the very last moment.

In the very last phase of negotiations by MEPs on their report, the COVI-secretariat suddenly received a questionnaire sent by HERA (Emergency Preparedness and Response Authority, the newly created EC agency) with the accompanying message that 'answers to these questions could accelerate the handling of the access request from COVI to the contracts'.

It raised some eyebrows, not only because of the lousy timing, but because the questionnaire was written by ... Pfizer.

The pharmaceutical company largely wanted to know from MEPs why they wanted information from non-redacted contracts including information on issues as liability and pricing, and what they would do with it.

Fuente: EU Observer. Disponible en https://euobserver.com/opinion/157234

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/07/01 to 2023/07/10. "COVID-19 vaccine" (Title/Abstract) 377 records.

Strategies to Address COVID-19 Vaccine and Pregnancy Myths.
Berkowitz HE, Vann JCJ. MCN Am J Matern Child Nurs. 2023 Jul-Aug 01;48(4):215-223. doi: 10.1097/NMC.0000000000000926. PMID: 36943837

An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding.
Blumenthal KG, Greenhawt M, Phillips EJ, Agmon-Levin N, Golden DB, Shaker M. J Allergy Clin Immunol Pract. 2023 Jul 4:S2213-2198(23)00723-7. doi: 10.1016/j.jaip.2023.06.057. Online ahead of print. PMID: 37414339

Diabetes, COVID-19, and questions unsolved.
D'Souza F, Buzzetti R, Pozzilli P. Diabetes Metab Res Rev. 2023 Jul;39(5):e3666. doi: 10.1002/dmrr.3666. Epub 2023 May 20. PMID: 37209039

COVID-19 vaccine hesitancy among pregnant and postpartum Kenyan women.
Marwa MM, Kinuthia J, Larsen A, Dettinger JC, Gomez LA, Awino P, Abuna F, Watoyi S, Ochieng B, Ngumbau N, John-Stewart G, Pintye J. Int J Gynaecol Obstet. 2023 Jul;162(1):147-153. doi: 10.1002/ijgo.14773. Epub 2023 Apr 10. PMID: 37036449

COVID-19 vaccine attitudes and facilitators among people in Australia who inject drugs.
Price O, Maher L, Dietze PM, Bruno R, Crawford S, Sutherland R, Salom C, Dore GJ, Peacock A. Drug Alcohol Rev. 2023 Jul;42(5):1066-1077. doi: 10.1111/dar.13621. Epub 2023 Feb 21. PMID: 36802338

Shot in the dark.
Bhatti MT, Gilbert AL, Watson G, Waheed M, Spencer D. Surv Ophthalmol. 2023 Jul-Aug;68(4):821-829. doi: 10.1016/j.survophthal.2022.09.003. Epub 2022 Sep 21. PMID: 36150481

Global acceptance of COVID-19 vaccine among persons with diabetes: A systematic review and meta-analysis.
Ekpor E, Akyirem S. Diabetes Res Clin Pract. 2023 Jul;201:110731. doi: 10.1016/j.diabres.2023.110731. Epub 2023 May 24. PMID: 37236364

The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study.
Gastelum-Strozzi A, Flores-Alvarado DE, Pascual-Ramos V, Álvarez-Hernández E, Pacheco-Tena CF, Guaracha-Basáñez GA, García CG, González-Chávez SA, Moctezuma-Ríos JF, Manrique de Lara A, Esquivel-Valerio JA, Contreras-Yáñez I, Galarza-Delgado DÁ, Vázquez-Mellado J, Peláez-Ballestas I, Reyes-Cordero GC. Rheumatol Int. 2023 Jul;43(7):1253-1264. doi: 10.1007/s00296-023-05334-1. Epub 2023 May 2. PMID: 37129609

Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections.
Ojha R, Singh S, Gupta N, Kumar K, Padhi AK, Prajapati VK. Biotechnol Lett. 2023 Jul;45(7):779-797. doi: 10.1007/s10529-023-03380-0. Epub 2023 May 6. PMID: 37148345

Vaccination in pregnancy.
Nassar AH, Hobeika E, Chamsy D, El-Kak F, Usta IM. Int J Gynaecol Obstet. 2023 Jul;162(1):18-23. doi: 10.1002/ijgo.14876. Epub 2023 Jun 7. PMID: 37283471

Hydrogels for RNA delivery.
Zhong R, Talebian S, Mendes BB, Wallace G, Langer R, Conde J, Shi J. Nat Mater. 2023 Jul;22(7):818-831. doi: 10.1038/s41563-023-01472-w. Epub 2023 Mar 20. PMID: 36941391

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.
Naveen R, Parodis I, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Nune A, Shinjo SK, Salim B, Ziade N, Velikova T, Edgar Gracia-Ramos A, Saavedra MA, Day J, Makol A, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Nikiphorou E; COVAD Study Group. Rheumatology (Oxford). 2023 Jul 5;62(7):2366-2376. doi: 10.1093/rheumatology/keac624. PMID: 36315075

Correlations between attitudes towards the COVID-19 vaccine and psychiatric symptoms among pregnant women.
Ayık B, Yılmaz S. Int J Gynaecol Obstet. 2023 Jul;162(1):88-94. doi: 10.1002/ijgo.14647. Epub 2023 Jan 18. PMID: 36598269

Population Segmentation for COVID-19 Vaccine Outreach: A Clustering Analysis and Implementation in Missouri.
Chessen EG, Ganser ME, Paulish CA, Malik A, Wishner AG, Turabelidze G, Glenn JJ. J Public Health Manag Pract. 2023 Jul-Aug 01;29(4):563-571. doi: 10.1097/PHH.0000000000001740. Epub 2023 Apr 13. PMID: 37071050

COVID-19 vaccine acceptance among people living with HIV: A systematic review and meta-analysis.
Ejamo JY, Legese GL, Tesfaye YA, Liben FE. Trop Med Int Health. 2023 Jul 4. doi: 10.1111/tmi.13908. Online ahead of print. PMID: 37402693

COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis.
Ceban F, Kulzhabayeva D, Rodrigues NB, Di Vincenzo JD, Gill H, Subramaniapillai M, Lui LMW, Cao B, Mansur RB, Ho RC, Burke MJ, Rhee TG, Rosenblat JD, McIntyre RS. Brain Behav Immun. 2023 Jul;111:211-229. doi: 10.1016/j.bbi.2023.03.022. Epub 2023 Mar 27. PMID: 36990297

Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties.
Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Sonbol FI, Batiha GE. Clin Exp Med. 2023 Jul;23(3):679-688. doi: 10.1007/s10238-022-00836-x. Epub 2022 May 24. PMID: 35608715

Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis.
Stone CA Jr, Garvey LH, Nasser S, Lever C, Triggiani M, Parente R, Phillips EJ. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2008-2022. doi: 10.1016/j.jaip.2023.05.004. Epub 2023 May 12. PMID: 37182566

From COVID-19 Vaccine Hesitancy to Vaccine Acceptance: Results of a Longitudinal Survey.
Fisher KA, Nguyen N, Fouayzi H, Crawford S, Singh S, Dong M, Wittenberg R, Mazor KM. Public Health Rep. 2023 Jul-Aug;138(4):681-690. doi: 10.1177/00333549231176006. Epub 2023 May 27. PMID: 37243439

The effects of parents' vaccine hesitancy and COVID-19 vaccine literacy on attitudes toward vaccinating their children during the pandemic.
Bektas İ, Bektas M. J Pediatr Nurs. 2023 Jul-Aug;71:e70-e74. doi: 10.1016/j.pedn.2023.04.016. Epub 2023 Apr 26. PMID: 37142496

Urological complications after COVID 19 vaccine according to age, sex and manufacturer.
Shim SR, Kim KT, Park E, Pyun JH, Kim JH, Chung BI. World J Urol. 2023 Jul 3. doi: 10.1007/s00345-023-04481-1. Online ahead of print. PMID: 37400660

Cancer immunity and immunotherapy beyond COVID-19.
Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Cancer Immunol Immunother. 2023 Jul;72(7):2541-2548. doi: 10.1007/s00262-023-03411-9. Epub 2023 Mar 30. PMID: 36995489

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection.
Dogra P, Schiavone C, Wang Z, Ruiz-Ramírez J, Caserta S, Staquicini DI, Markosian C, Wang J, Sostman HD, Pasqualini R, Arap W, Cristini V. JCI Insight. 2023 Jul 10;8(13):e169860. doi: 10.1172/jci.insight.169860. PMID: 37227783

Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin.
Kan AKC, Li PH. Immunol Lett. 2023 Jul;259:21-23. doi: 10.1016/j.imlet.2023.05.007. Epub 2023 May 23. PMID: 37230399

Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review.
Yeo S, Kim H, Lee J, Yi J, Chung YR. Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1793-1808. doi: 10.1007/s00417-022-05953-7. Epub 2023 Jan 4. PMID: 36598554

Tinnitus cases after COVID-19 vaccine administration, one institution's observations.
Lin D, Selleck AM. Am J Otolaryngol. 2023 Jul-Aug;44(4):103863. doi: 10.1016/j.amjoto.2023.103863. Epub 2023 Mar 24. PMID: 36989754

COVID-19 vaccination and fertility: fighting misinformation.
Mathur R. Obstet Gynaecol Reprod Med. 2023 Jul;33(7):203-204. doi: 10.1016/j.ogrm.2023.04.004. Epub 2023 Apr 7. PMID: 37363425

Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes.
Li M, Wu X, Shi J, Niu Y. Endocrine. 2023 Jul 1. doi: 10.1007/s12020-023-03439-y. Online ahead of print. PMID: 37392341

Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.
Yin S, Ren J, Xue J, Li P, Luo J, Yin J, Luo L, Li Z, Luo G. Int J Infect Dis. 2023 Jul;132:9-16. doi: 10.1016/j.ijid.2023.04.393. Epub 2023 Apr 15. PMID: 37068582

A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.
Su P, Wu Y, Xie F, Zheng Q, Chen L, Liu Z, Meng X, Zhou F, Zhang L. Adv Sci (Weinh). 2023 Jul;10(19):e2206095. doi: 10.1002/advs.202206095. Epub 2023 May 5. PMID: 37144543

COVID-19 vaccination in pregnancy: Need for global pharmaco-vigilance.
Sarwal Y, Sarwal R. Int J Gynaecol Obstet. 2023 Jul;162(1):24-28. doi: 10.1002/ijgo.14646. Epub 2023 Jan 27. PMID: 36617690

Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.
Naveen R, Thakare DR, Kuwana M, Pauling JD, Day J, Joshi M, Parodis I, Sen P, Jagtap K, Nikiphorou E, Saha S, Agarwal V, Chatterjee T, Lilleker JB, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Chinoy H; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Makol A. Rheumatol Int. 2023 Jul;43(7):1265-1275. doi: 10.1007/s00296-023-05310-9. Epub 2023 Mar 31. PMID: 37000295

Associations between COVID-19 Death Exposure and COVID-19 Vaccine Hesitancy and Vaccine Uptake.
Andersen JA, Scott AJ, Rowland B, Willis DE, McElfish PA. South Med J. 2023 Jul;116(7):519-523. doi: 10.14423/SMJ.0000000000001576. PMID: 37400094

The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection.
Xue VW, Wong SCC, Li B, Cho WCS. Expert Opin Drug Discov. 2023 Jul;18(7):769-780. doi: 10.1080/17460441.2023.2218083. Epub 2023 May 26. PMID: 37237360

COVID-19 Vaccine Hesitancy Among Patients Recovered From COVID-19 Infection in Wuhan, China: Cross-Sectional Questionnaire Study.
Huang Y, Zhang L, Fu J, Wu Y, Wang H, Xiao W, Xin Y, Dai Z, Si M, Chen X, Jia M, Leng Z, Cui D, Su X. JMIR Public Health Surveill. 2023 Jul 3;9:e42958. doi: 10.2196/42958. PMID: 37247615

COVID-19 Vaccination Status and Operative Outcomes after Kidney Transplantation.
Kushner BS, Doyle MB, Khan AS, Lin Y, Alhamad T, Yu J, Chapman WC, Wellen JR. J Am Coll Surg. 2023 Jul 1;237(1):139-145. doi: 10.1097/XCS.0000000000000657. Epub 2023 Feb 17. PMID: 36799500

Antigen Delivery Systems: Past, Present, and Future.
Ko HJ, Kim YJ. Biomol Ther (Seoul). 2023 Jul 1;31(4):370-387. doi: 10.4062/biomolther.2023.006. Epub 2023 Apr 19. PMID: 37072288

When Adolescents Disagree with Their Vaccine-Hesitant Parents about COVID-19 Vaccination.
Olick RS, Yang YT, Shaw J. J Clin Ethics. 2023 Summer;34(2):158-168. doi: 10.1086/724746. PMID: 37229735

COVID-19: Findings in nuclear medicine from head to toe.
Vaz N, Franquet E, Heidari P, Chow DZ, Jacene HA, Ng TSC. Clin Imaging. 2023 Jul;99:10-18. doi: 10.1016/j.clinimag.2023.04.003. Epub 2023 Apr 8. PMID: 37043868

Long-Term Dynamic of Anti-TrimericS and Anti-RBD Antibodies in Naive and COVID-19 Recovered mRNA-1273 Vaccine Recipients.
Ocmant A, Roisin S, Mathieu D, Brauner J, De Leener F. Lab Med. 2023 Jul 5;54(4):388-391. doi: 10.1093/labmed/lmac127. PMID: 36493367

Association Between Racial Segregation and COVID-19 Vaccination Rates.
Swietek K, Gianattasio KZ, Henderson S, Khanna S, Ubri P, Douglas M, Baltrus P, Freij M, Mack DH, Gaglioti A. J Public Health Manag Pract. 2023 Jul-Aug 01;29(4):572-579. doi: 10.1097/PHH.0000000000001738. Epub 2023 Mar 17. PMID: 36943401

COVID-19 vaccination and the behavioral immune system: The newcomer and the old friend get along in preventing infection.
Troisi A, Croce Nanni R, De Sanctis S, Dieguez G, Carola V. Brain Behav Immun Health. 2023 Jul;30:100621. doi: 10.1016/j.bbih.2023.100621. Epub 2023 Apr 7. PMID: 37063495

Motivators and Barriers to COVID-19 Vaccination in Young Adults Living in the USA.
Lee YM, Simonovich SD, Li S, Amer L, Wagner L, Hill J, Spulark R, Aquino E. Clin Nurs Res. 2023 Jul;32(6):971-982. doi: 10.1177/10547738231177331. Epub 2023 Jun 2. PMID: 37264835

Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19.
Picone P, Sanfilippo T, Guggino R, Scalisi L, Monastero R, Baschi R, Mandalà V, San Biagio L, Rizzo M, Giacomazza D, Dispenza C, Nuzzo D. Cell Mol Neurobiol. 2023 Jul;43(5):1685-1695. doi: 10.1007/s10571-022-01281-w. Epub 2022 Sep 14. PMID: 36103031

Decision-Making about COVID-19 Vaccines among Health Care Workers and Their Adolescent Children.
Mansfield LN, Choi K, Delgado JR, Macias M, Munoz-Plaza C, Lewin B, Bronstein D, Chang J, Bruxvoort K. West J Nurs Res. 2023 Jul;45(7):665-673. doi: 10.1177/01939459231170981. Epub 2023 Apr 24. PMID: 37096318

Monkeypox vaccination in the global south: Fighting a war without a weapon.
Ogunkola IO, Abiodun OE, Bale BI, Elebesunu EE, Ujam SB, Umeh IC, Tom-James M, Musa SS, Manirambona E, Evardone SB, Lucero-Prisno DE 3rd. Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101313. doi: 10.1016/j.cegh.2023.101313. Epub 2023 May 19. PMID: 37220529

Management and outcome of COVID-19 in CTLA-4 insufficiency.
Ochoa Gonzalez S, Abers MS, Rosen LB, Rump A, Howe KN, Lieberman JA, Wright BL, Suez D, Krausz M, Grimbacher B, Lionakis MS, Uzel G. Blood Adv. 2023 Jul 5:bloodadvances.2023010105. doi: 10.1182/bloodadvances.2023010105. Online ahead of print. PMID: 37406177

Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development.
Koff WC, Rappuoli R, Plotkin SA. J Mol Biol. 2023 Jul 1;435(13):168113. doi: 10.1016/j.jmb.2023.168113. Epub 2023 Apr 18. PMID: 37080423

Learning from cancer to address COVID-19.
Oláh E. Biol Futur. 2023 Jul 6. doi: 10.1007/s42977-023-00156-5. Online ahead of print. PMID: 37410273

Current challenges and perspectives in lung cancer care during COVID-19 waves.
Mariniello DF, Aronne L, Vitale M, Schiattarella A, Pagliaro R, Komici K. Curr Opin Pulm Med. 2023 Jul 1;29(4):239-247. doi: 10.1097/MCP.0000000000000967. Epub 2023 May 2. PMID: 37132294

Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.
Chenchula S, Amerneni KC, Ghanta MK, Padmavathi R, Chandra MB, Adusumilli MB, Chavan M, Mudda S, Gupta R, Lakhawat B. Virology. 2023 Jul;584:38-43. doi: 10.1016/j.virol.2023.04.007. Epub 2023 May 19. PMID: 37229914

COVID-19 vaccine hesitancy among pregnant women attending tertiary care centre: A cross-sectional study.
Gupta N, Sharma S, Nigam A, Panasar S, Kumar S. Int J Gynaecol Obstet. 2023 Jul;162(1):70-77. doi: 10.1002/ijgo.14794. Epub 2023 Apr 20. PMID: 37078596

Insights into new-onset autoimmune diseases after COVID-19 vaccination.
Guo M, Liu X, Chen X, Li Q. Autoimmun Rev. 2023 Jul;22(7):103340. doi: 10.1016/j.autrev.2023.103340. Epub 2023 Apr 17. PMID: 37075917

COVID-19 vaccinations and mental health among U.S. adults: Individual and spillover effects.
Coley RL, Carey N, Baum CF, Hawkins SS. Soc Sci Med. 2023 Jul;329:116027. doi: 10.1016/j.socscimed.2023.116027. Epub 2023 Jun 13. PMID: 37331285

A case of fatal multi-organ inflammation following COVID-19 vaccination.
Nushida H, Ito A, Kurata H, Umemoto H, Tokunaga I, Iseki H, Nishimura A. Leg Med (Tokyo). 2023 Jul;63:102244. doi: 10.1016/j.legalmed.2023.102244. Epub 2023 Mar 20. PMID: 36990036

Standing alone: experiences of vaccine-hesitant Danish healthcare professionals during COVID-19.
Marså K, Kristensen TB, Konradsen H. Scand J Public Health. 2023 Jul;51(5):711-717. doi: 10.1177/14034948221113645. Epub 2022 Aug 29. PMID: 36032021

Subacute cutaneous lupus erythematosus after COVID-19 vaccine.
Wang YJ, Hui HZ, Cheng JR, Mao H, Shi BJ. Int J Rheum Dis. 2023 Jul;26(7):1407-1409. doi: 10.1111/1756-185X.14640. Epub 2023 Mar 7. PMID: 36880735

COVID-19 Vaccine Acceptance Among Latino/a Immigrants: The Role of Collective Responsibility and Confidence.
Kirchoff C, Penn A, Wang W, Babino R, De La Rosa M, Cano MA, Sanchez M. J Immigr Minor Health. 2023 Jul 4. doi: 10.1007/s10903-023-01513-1. Online ahead of print. PMID: 37402075

Vaccine envy during the COVID-19 pandemic.
Erz E, Rentzsch K. Int J Psychol. 2023 Jul 10. doi: 10.1002/ijop.12929. Online ahead of print. PMID: 37427842

Unvaccinated Adolescents' COVID-19 Vaccine Intentions: Implications for Public Health Messaging.
Ryan GW, Askelson NM, Woodworth KR, Lindley MC, Gedlinske A, Parker AM, Gidengil CA, Petersen CA, Scherer AM. J Adolesc Health. 2023 Jul 3:S1054-139X(23)00282-3. doi: 10.1016/j.jadohealth.2023.05.023. Online ahead of print. PMID: 37395695

Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years.
Hu M, Wong HL, Feng Y, Lloyd PC, Smith ER, Amend KL, Kline A, Beachler DC, Gruber JF, Mitra M, Seeger JD, Harris C, Secora A, Obidi J, Wang J, Song J, McMahill-Walraven CN, Reich C, McEvoy R, Do R, Chillarige Y, Clifford R, Cooper DD, Shoaibi A, Forshee R, Anderson SA. JAMA Pediatr. 2023 Jul 1;177(7):710-717. doi: 10.1001/jamapediatrics.2023.1440. PMID: 37213095

Factors related to COVID-19 vaccine hesitancy in Denmark: A national study in the autumn of 2021.
Rosenkilde S, Ekholm O, Møller SP, Nielsen MBD, Thygesen LC. Scand J Public Health. 2023 Jul;51(5):780-785. doi: 10.1177/14034948221144661. Epub 2023 Jan 6. PMID: 36609202

Do COVID-19 viral infection and its mRNA vaccine carry an equivalent risk of myocarditis? Review of the current evidence, insights, and future directions.
Ulucay AS, Singh G, Kanuri SH. Indian Heart J. 2023 Jul 1:S0019-4832(23)00110-4. doi: 10.1016/j.ihj.2023.06.009. Online ahead of print. PMID: 37399904

Lessons Learned From Monitoring Spanish-Language Vaccine Misinformation During the COVID-19 Pandemic.
Bonnevie E, Ricciulli V, Fields M, O'Neill R. Public Health Rep. 2023 Jul-Aug;138(4):586-592. doi: 10.1177/00333549231168452. Epub 2023 Apr 27. PMID: 37102367

Physician stress in the era of COVID-19 vaccine disparity: a multi-institutional survey.
Zahl S, Mondal D, Tolentino D, Fischer JA, Jimenez S. J Osteopath Med. 2023 Apr 19;123(7):351-355. doi: 10.1515/jom-2022-0194. eCollection 2023 Jul 1. PMID: 37079908

Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech).
Akiyama Y, Inagaki T, Morioka S, Kusano E, Ohmagari N. Intern Med. 2023 Jul 1;62(13):2013-2017. doi: 10.2169/internalmedicine.1682-23. Epub 2023 Apr 21. PMID: 37081683

Longitudinal Association Between Social Isolation and COVID-19 Vaccine Uptake in Japanese Older Citizen: an Observational Study.
Yamada Y, Ogawa Y, Shimizu S, Matsuoka Y, Yamamoto Y. J Gen Intern Med. 2023 Jul 5. doi: 10.1007/s11606-023-08286-1. Online ahead of print. PMID: 37407768

Evaluation of Willingness to Accept COVID-19 Vaccine and Willingness to Pay among Pakistani Parents for Their Children Aged 5 to 11 Years: Findings and Implications.
Hayat K, Farooq Umer M, Mujtaba H, Babar Kawish A, Azam Tahir M, Ullah Khan F, Ullah Khan F, Omer Iqbal M, Hussain T, Ur Rehman A, Fang Y. Am J Trop Med Hyg. 2023 May 15;109(1):69-75. doi: 10.4269/ajtmh.22-0363. Print 2023 Jul 5. PMID: 37188339

DNA-scaffolded multivalent vaccine against SARS-CoV-2.
Chen F, Huang Y, Huang Z, Jiang T, Yang Z, Zeng J, Jin A, Zuo H, Huang CZ, Mao C. Acta Biomater. 2023 Jul 1;164:387-396. doi: 10.1016/j.actbio.2023.04.017. Epub 2023 Apr 22. PMID: 37088158

"This is most likely not the correct vaccine": Analyzing COVID-19's viral spread and vaccine anxieties in Ghana, Cameroon, and Malawi.
Ojong N, Agbe E. Soc Sci Med. 2023 Jul;329:116001. doi: 10.1016/j.socscimed.2023.116001. Epub 2023 May 31. PMID: 37327597

Estimating the delivery costs of COVID-19 vaccination using the COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool: the Lao People's Democratic Republic experience.
Yeung KHT, Kim E, Yap WA, Pathammavong C, Franzel L, Park YL, Cowley P, Griffiths UK, Hutubessy RCW. BMC Med. 2023 Jul 10;21(1):248. doi: 10.1186/s12916-023-02944-1. PMID: 37424001

The effectiveness of financial incentives for COVID-19 vaccination: A systematic review.
Khazanov GK, Stewart R, Pieri MF, Huang C, Robertson CT, Schaefer KA, Ko H, Fishman J. Prev Med. 2023 Jul;172:107538. doi: 10.1016/j.ypmed.2023.107538. Epub 2023 May 6. PMID: 37156430

Predictors of second COVID-19 booster dose or new COVID-19 vaccine hesitancy among nurses: A cross-sectional study.
Galanis P, Vraka I, Katsiroumpa A, Siskou O, Konstantakopoulou O, Katsoulas T, Mariolis-Sapsakos T, Kaitelidou D. J Clin Nurs. 2023 Jul;32(13-14):3943-3953. doi: 10.1111/jocn.16576. Epub 2022 Nov 7. PMID: 36345133

An Organizational Assessment of 34 Home Delivered Meals Programs that Engaged and Assisted Homebound Individuals With Obtaining the COVID-19 Vaccine During the Pandemic.
Guglielmo D, Cloud J, Trejo L, Baca C, Smith LV, Shetgiri R, Kuo T; Homebound Data Workgroup. J Appl Gerontol. 2023 Jul;42(7):1497-1504. doi: 10.1177/07334648231157583. Epub 2023 Feb 16. PMID: 36797836

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, Babbage G, Baker J, Baxter D, Bawa T, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Fox L, Qureshi E, Goodman AL, Green CA, Haughney J, Hicks A, Jones CE, Kanji N, van der Klaauw AA, Libri V, Llewelyn MJ, Mansfield R, Maallah M, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Belhadef HT, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Saralaya D, Sharma S, Sheridan R, Stokes M, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. J Infect. 2023 Jul;87(1):18-26. doi: 10.1016/j.jinf.2023.04.012. Epub 2023 Apr 20. PMID: 37085049

Identity resilience, science mistrust, COVID-19 risk and fear predictors of vaccine positivity and vaccination likelihood: A survey of UK and Portuguese samples.
Breakwell GM, Jaspal R, Wright DB. J Health Psychol. 2023 Jul;28(8):747-759. doi: 10.1177/13591053231161891. Epub 2023 Mar 26. PMID: 36967590

Tackling Counterfeit Drugs: The Challenges and Possibilities.
Pathak R, Gaur V, Sankrityayan H, Gogtay J. Pharmaceut Med. 2023 Jul;37(4):281-290. doi: 10.1007/s40290-023-00468-w. Epub 2023 May 15. PMID: 37188891

COVID-19 vaccination and decreased death rates: A county-level study in Pennsylvania.
Ramunno M, Savitz R. J Med Virol. 2023 Jul;95(7):e28883. doi: 10.1002/jmv.28883. PMID: 37394791

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Tang R, Zheng H, Wang BS, Gou JB, Guo XL, Chen XQ, Chen Y, Wu SP, Zhong J, Pan HX, Zhu JH, Xu XY, Shi FJ, Li ZP, Liu JX, Zhang XY, Cui LB, Song ZZ, Hou LH, Zhu FC, Li JX; CanSino COVID-19 Study Group. Lancet Respir Med. 2023 Jul;11(7):613-623. doi: 10.1016/S2213-2600(23)00049-8. Epub 2023 Mar 7. PMID: 36898400

What determines Hong Kong South Asians' perceptions on COVID-19 vaccine? Implications on culturally appropriate vaccine messages for ethnic minority community.
Lai AH, Wang JZ, Singh A, Wong EL, Wang K, Yeoh EK. J Community Psychol. 2023 Jul;51(6):2442-2464. doi: 10.1002/jcop.22920. Epub 2022 Jul 23. PMID: 35869946

COVID-19, Genetics, and Risk: Content Analysis of Facebook Posts Early in the Coronavirus Pandemic.
Canary HE, Wellman N, Martinez LS. Health Commun. 2023 Jul;38(8):1654-1665. doi: 10.1080/10410236.2022.2027639. Epub 2022 Jan 23. PMID: 35067113

Preferences for COVID-19 Vaccination in People With Chronic Immune-Mediated Inflammatory Diseases.
Hazlewood GS, Colmegna I, Hitchon C, Fortin PR, Bernatsky S, Clarke AE, Mosher D, Wilson T, Thomas M, Barber CEH, Harrison M, Bansback N, Proulx L, Richards DP, Kaplan GG. J Rheumatol. 2023 Jul;50(7):949-957. doi: 10.3899/jrheum.220697. Epub 2023 Jan 15. PMID: 36642432

Epidemic retinitis during the COVID-19 pandemic.
Kawali A, Srinivasan S, Mishra SB, Mahendradas P, Shetty B. Indian J Ophthalmol. 2023 Jul;71(7):2779-2783. doi: 10.4103/IJO.IJO_3349_22. PMID: 37417120

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases.
Saputra PBT, Kurniawan RB, Trilistyoati D, Farabi MJA, Susilo H, Alsagaff MY, Oktaviono YH, Sutanto H, Gusnanto A, Dyah Kencono Wungu C. Biomol Biomed. 2023 Jul 3;23(4):546-567. doi: 10.17305/bb.2022.8779. PMID: 36803547

Strategies to reduce COVID-19 vaccine hesitancy among pregnant individuals: Data from a prospective survey of unvaccinated pregnant women.
Binger K, Cui Y, Kelly JA, Palatnik A. Int J Gynaecol Obstet. 2023 Jul;162(1):95-104. doi: 10.1002/ijgo.14799. Epub 2023 Apr 26. PMID: 37102200

COVID-19 vaccination, incidence, and mortality rates among individuals with mental disorders in South Korea: A nationwide retrospective study.
Lee DW, Bae YS, Lee JR, Sohn JH, Lee H, Lee JY. Asian J Psychiatr. 2023 Jul;85:103600. doi: 10.1016/j.ajp.2023.103600. Epub 2023 Apr 25. PMID: 37163942

Intentions to be Vaccinated Against COVID-19: The Role of Prosociality and Conspiracy Beliefs across 20 Countries.
Enea V, Eisenbeck N, Carreno DF, Douglas KM, Sutton RM, Agostini M, Bélanger JJ, Gützkow B, Kreienkamp J, Abakoumkin G, Abdul Khaiyom JH, Ahmedi V, Akkas H, Almenara CA, Atta M, Bagci SC, Basel S, Berisha Kida E, Bernardo ABI, Buttrick NR, Chobthamkit P, Choi HS, Cristea M, Csaba S, Damnjanovic K, Danyliuk I, Dash A, Di Santo D, Faller DG, Fitzsimons G, Gheorghiu A, Gómez Á, Grzymala-Moszczynska J, Hamaidia A, Han Q, Helmy M, Hudiyana J, Jeronimus BF, Jiang DY, Jovanović V, Kamenov Ž, Kende A, Keng SL, Kieu TTT, Koc Y, Kovyazina K, Kozytska I, Krause J, Kruglanski AW, Kurapov A, Kutlaca M, Lantos NA, Lemay EP, Lesmana CBJ, Louis WR, Lueders A, Malik NI, Martinez A, McCabe KO, Mehulić J, Milla MN, Mohammed I, Molinario E, Moyano M, Muhammad H, Mula S, Muluk H, Myroniuk S, Najafi R, Nisa CF, Nyúl B, O'Keefe PA, Osuna JJO, Osin EN, Park J, Pica G, Pierro A, Rees J, Reitsema AM, Resta E, Rullo M, Ryan MK, Samekin A, Santtila P, Sasin E, Schumpe BM, Selim HA, Stanton MV, Sultana S, Tseliou E, Utsugi A, van Breen JA, Van Lissa CJ, Van Veen K, vanDellen MR, Vázquez A, Wollast R, Yeung VW, Zand S, Žeželj IL, Zheng B, Zick A, Zúñiga C, Leander NP. Health Commun. 2023 Jul;38(8):1530-1539. doi: 10.1080/10410236.2021.2018179. Epub 2022 Jan 26. PMID: 35081848

The experiences and attitudes of family caregivers of adults with intellectual and developmental disabilities at different timepoints in the COVID-19 pandemic.
Tarzi G, Mendoza O, Lunsky Y, St John L. Disabil Health J. 2023 Jul;16(3):101472. doi: 10.1016/j.dhjo.2023.101472. Epub 2023 Apr 6. PMID: 37120390

Vaccination during pregnancy: A golden opportunity to embrace.
Amaral E, Money D, Jamieson D, Pasupathy D, Aronoff D, Jacobsson B, Lizcano EIO; FIGO Committee on Infections During Pregnancy*. Int J Gynaecol Obstet. 2023 Jul 7. doi: 10.1002/ijgo.14981. Online ahead of print. PMID: 37417315

Individual-level determinants of COVID-19 vaccination in pregnant people in East Tennessee.
Ehrlich SF, Maples J, Burnette S, Rand B, Zite N, Paudel A, Fortner K. Int J Gynaecol Obstet. 2023 Jul;162(1):6-12. doi: 10.1002/ijgo.14698. Epub 2023 Mar 11. PMID: 36807907

Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Klineova S, Farber RS, DeAngelis T, Leung T, Smith T, Blanck R, Zhovtis-Ryerson L, Harel A. Mult Scler. 2023 Jul;29(8):990-1000. doi: 10.1177/13524585231185246. PMID: 37431628

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
Chemaitelly H, Ayoub HH, Tang P, Coyle P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Faust JS, Abu-Raddad LJ. Lancet Infect Dis. 2023 Jul;23(7):816-827. doi: 10.1016/S1473-3099(23)00058-0. Epub 2023 Mar 10. PMID: 36913963

Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis.

Kitano T, Thompson DA, Engineer L, Dudley MZ, Salmon DA. Am J Epidemiol. 2023 Jul 7;192(7):1137-1147. doi: 10.1093/aje/kwad058. PMID: 36920222

Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
He X, He C, Hong W, Yang J, Wei X. Med Res Rev. 2023 Jul;43(4):932-971. doi: 10.1002/med.21941. Epub 2023 Mar 16. PMID: 36929527

Myotonic dystrophy type 1 in the COVID-19 era.
Ilic Zivojinovic J, Djurdjevic K, Bozovic I, Meola G, Peric M, Azanjac Arsic A, Basta I, Rakocevic-Stojanovic V, Peric S. Neurol Sci. 2023 Jul;44(7):2231-2237. doi: 10.1007/s10072-023-06834-5. Epub 2023 May 8. PMID: 37155112

Upscaling vaccine manufacturing capacity - key bottlenecks and lessons learned.
Feddema JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM. Vaccine. 2023 Jul 5;41(30):4359-4368. doi: 10.1016/j.vaccine.2023.05.027. Epub 2023 Jun 3. PMID: 37277250

Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Selvadurai MV, Favaloro EJ, Chen VM. Semin Thromb Hemost. 2023 Jul;49(5):444-452. doi: 10.1055/s-0043-1761269. Epub 2023 Jan 27. PMID: 36706782

COVID-19 vaccination status and related process of care outcomes.
Kleebayoon A, Wiwanitkit V. Epilepsy Behav. 2023 Jul;144:109262. doi: 10.1016/j.yebeh.2023.109262. Epub 2023 May 24. PMID: 37276804

Curious Questions About Covid-19 Pandemic with ChatGPT: Answers and Recommendations.
Tekinay ON. Ann Biomed Eng. 2023 Jul;51(7):1371-1373. doi: 10.1007/s10439-023-03209-x. Epub 2023 Apr 18. PMID: 37071282

Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
Wang Y, Luangasanatip N, Pan-Ngum W, Isaranuwatchai W, Prawjaeng J, Saralamba S, Painter C, Briones JR, Teerawattananon Y. Eur J Health Econ. 2023 Jul;24(5):735-748. doi: 10.1007/s10198-022-01505-2. Epub 2022 Aug 11. PMID: 35951243

Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
Zamani P, Mashreghi M, Rezazade Bazaz M, Zargari S, Alizadeh F, Dorrigiv M, Abdoli A, Aminianfar H, Hatamipour M, Zarqi J, Behboodifar S, Samsami Y, Khorshid Sokhangouy S, Sefidbakht Y, Uskoković V, Rezayat SM, Jaafari MR, Mozaffari-Jovin S. J Control Release. 2023 Jul 5;360:316-334. doi: 10.1016/j.jconrel.2023.06.025. Online ahead of print. PMID: 37355212

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations.
Cowan J, Amson A, Christofides A, Chagla Z. Int J Infect Dis. 2023 Jul 1:S1201-9712(23)00645-8. doi: 10.1016/j.ijid.2023.06.021. Online ahead of print. PMID: 37400053

Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave - a nationwide study in Japan.
Tanaka H, Chubachi S, Asakura T, Namkoong H, Azekawa S, Otake S, Nakagawara K, Fukushima T, Lee H, Watase M, Sakurai K, Kusumoto T, Masaki K, Kamata H, Ishii M, Hasegawa N, Okada Y, Koike R, Kitagawa Y, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K. Int J Infect Dis. 2023 Jul;132:84-88. doi: 10.1016/j.ijid.2023.04.399. Epub 2023 Apr 21. PMID: 37086866

The impact of COVID-19 related adversity on the course of mental health during the pandemic and the role of protective factors: a longitudinal study among older adults in The Netherlands.
Holwerda TJ, Jaarsma E, van Zutphen EM, Beekman ATF, Pan KY, van Vliet M, Stringa N, van den Besselaar JH, MacNeil-Vroomen JL, Hoogendijk EO, Kok AAL. Soc Psychiatry Psychiatr Epidemiol. 2023 Jul;58(7):1109-1120. doi: 10.1007/s00127-023-02457-5. Epub 2023 Mar 25. PMID: 36964770

The attitude and knowledge of pediatricians and family physicians toward COVID-19 vaccination in children: A cross-sectional study.
Alfaqih MA, Ababneh EY, Almansi GA, Marashdeh SA, Khazandar AA, Said AM, Mustafa AG. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230104. doi: 10.1080/21645515.2023.2230104. Epub 2023 Jul 3. PMID: 37395614

Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England.
Atchison CJ, Whitaker M, Donnelly CA, Chadeau-Hyam M, Riley S, Darzi A, Ashby D, Barclay W, Cooke GS, Elliott P, Ward H. Arch Dis Child. 2023 Jul;108(7):e12. doi: 10.1136/archdischild-2022-325152. Epub 2023 Mar 2. PMID: 36863848

Therapeutic role of traditionally used Indian medicinal plants and spices in combating COVID-19 pandemic situation.
Nath M, Debnath P. J Biomol Struct Dyn. 2023 Jul-Aug;41(12):5894-5913. doi: 10.1080/07391102.2022.2093793. Epub 2022 Jun 30. PMID: 35773779

Seronegative acute encephalitis following COVID-19 vaccines: a case series of an overlooked diagnosis with literature review.
Mansour K, Chadli Z, Ghachem I, Fredj NB, Romdhane HB, Fadhel NB, Boughatas N, Aouam K, Chaabane A, Younes S. Eur J Clin Pharmacol. 2023 Jul;79(7):975-987. doi: 10.1007/s00228-023-03510-7. Epub 2023 May 26. PMID: 37231308

Timely Second-Dose Completion of mRNA COVID-19 Vaccination at Community-Based and Mobile Vaccine Clinics in Maryland.
Parent C, Bigelow BF, Sisson SD, Martínez D, Yang C, Page KR. Am J Public Health. 2023 Jul 6:e1-e5. doi: 10.2105/AJPH.2023.307338. Online ahead of print. PMID: 37410982

mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M, Demir S, Arslan G, Dinç Ö, Şen S, Gündüz T, Uzunköprü C, Gümüş H, Tütüncü M, Akçin R, Özakbaş S, Köseoğlu M, Bünül SD, Gezen O, Tezer DÇ, Baba C, Özen PA, Koç R, Elverdi T, Uygunoğlu U, Kürtüncü M, Beckmann Y, Doğan İG, Turan ÖF, Boz C, Terzi M, Tuncer A, Saip S, Karabudak R,

Kocazeybek B, Efendi H, Bilge U, Siva A. Mult Scler Relat Disord. 2023 Jul;75:104761. doi: 10.1016/j.msard.2023.104761. Epub 2023 May 10. PMID: 37247488

"Vitreous Hemorrhage and Long-Lasting Priapism After COVID-19 m-RNA Based Vaccine: A Case Report".
Casarini B, Bruni F, Rubino P, Mora P. Eur J Ophthalmol. 2023 Jul;33(4):NP62-NP65. doi: 10.1177/11206721221098880. Epub 2022 May 3. PMID: 35505605

Prevalence of New-Onset Tinnitus after COVID-19 Vaccination with Comparison to Other Vaccinations.
Dorney I, Bobak L, Otteson T, Kaelber DC. Laryngoscope. 2023 Jul;133(7):1722-1725. doi: 10.1002/lary.30395. Epub 2022 Sep 13. PMID: 36098476

Evaluation of T and B cell immunophenotyping and antibody response post Covid-19 vaccination.
Chadha R, Ds U, Phogat R, Alam S, Mathur N, Singh M, Kataria S, Sharma P, Singh P, Sarma S, Saxena R, Ganguly NK, Trehan N. Indian J Med Microbiol. 2023 Jul-Aug;44:100372. doi: 10.1016/j.ijmmb.2023.100372. Epub 2023 May 16. PMID: 37356831

mRNA: A promising platform for cancer immunotherapy.
Kong B, Kim Y, Kim EH, Suk JS, Yang Y. Adv Drug Deliv Rev. 2023 Jul 4;199:114993. doi: 10.1016/j.addr.2023.114993. Online ahead of print. PMID: 37414361

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Clin Microbiol Infect. 2023 Jul;29(7):918-923. doi: 10.1016/j.cmi.2023.03.007. Epub 2023 Mar 13. PMID: 36921715

Marketing of commercial milk formula during COVID-19 in Indonesia.
Hidayana I, Prawindarti L, Umar N, Ambarwati K, Rosatriani F. Matern Child Nutr. 2023 Jul;19(3):e13491. doi: 10.1111/mcn.13491. Epub 2023 Mar 9. PMID: 36891928

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults.
Whitehead HS, Songo J, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout JJ, Hoffman RM, Moucheraud C. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228168. doi: 10.1080/21645515.2023.2228168. Epub 2023 Jul 2. PMID: 37394430

How Do Religious and Political Beliefs Predict COVID-19 Vaccination Behavior Among U.S. College Students? A Study Using the Health Belief Model.
Chen Y. Am J Health Promot. 2023 Jul;37(6):786-795. doi: 10.1177/08901171231160666. Epub 2023 Mar 24. PMID: 36960940

Political variations in pandemic lifestyles and COVID-19 vaccination by age cohort in the United States.
Dowd-Arrow B, Burdette AM, Smith A. Prev Med. 2023 Jul;172:107525. doi: 10.1016/j.ypmed.2023.107525. Epub 2023 May 8. PMID: 37164162

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications.
Seida I, Alrais M, Seida R, Alwani A, Kiyak Z, Elsalti A, Nil Esirgun S, Abali T, Mahroum N. Clin Exp Immunol. 2023 Jul 5;213(1):87-101. doi: 10.1093/cei/uxad033. PMID: 36881788

Investigating the Possible Reasons for the Low Reported Morbidity and Mortality of COVID-19 in African Countries: An Integrative Review.
Manna OK, Costa Clemens SA, Clemens R. Pediatr Infect Dis J. 2023 Jul 1;42(7):e222-e228. doi: 10.1097/INF.0000000000003916. Epub 2023 Apr 3. PMID: 37054386

Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.
Cohen D, Izak M, Stoyanov E, Mandelboim M, Perlman S, Amir Y, Goren S, Bialik A, Kliker L, Atari N, Yshai R, Zaide Y, Marcus H, Madar-Balakirski N, Israely T, Paran N, Zimhony O, Shinar E, Maor Y, Muhsen K. Int J Infect Dis. 2023 Jul;132:72-79. doi: 10.1016/j.ijid.2023.04.395. Epub 2023 Apr 16. PMID: 37072052

Value of vaccine and vaccine excipient skin testing to COVID-19 vaccines.
Brockow K, Bent R, Biedermann T. Allergy. 2023 Jul;78(7):2064-2065. doi: 10.1111/all.15732. PMID: 37389865

Value of a confidential COVID-19 helpline for nursing home staff.
Gussin GM, Singh RD, Nguyen KP, Huang SS. Am J Infect Control. 2023 Jul;51(7):841-843. doi: 10.1016/j.ajic.2022.11.004. Epub 2022 Nov 18. PMID: 36403708

Examining thematic and emotional differences across Twitter, Reddit, and YouTube: The case of COVID-19 vaccine side effects.
Kwon S, Park A. Comput Human Behav. 2023 Jul;144:107734. doi: 10.1016/j.chb.2023.107734. Epub 2023 Mar 15. PMID: 36942128

The evolution of COVID-19 vaccine hesitancy in Sub-Saharan Africa: evidence from panel survey data.
Wollburg P, Markhof Y, Kanyanda S, Zezza A. BMC Proc. 2023 Jul 6;17(Suppl 7):8. doi: 10.1186/s12919-023-00266-x. PMID: 37415169

Women's attitude towards COVID-19 vaccination in pregnancy: A survey study in northern Italy.
Colciago E, Capitoli G, Vergani P, Ornaghi S. Int J Gynaecol Obstet. 2023 Jul;162(1):139-146. doi: 10.1002/ijgo.14506. Epub 2022 Oct 22. PMID: 36227124

Public Health Impacts of Vaccines for COVID-19 and Beyond: Opportunities to Overcome Technical and Regulatory Barriers for Randomized Trials.
Kennedy-Shaffer L. Am J Public Health. 2023 Jul;113(7):778-785. doi: 10.2105/AJPH.2023.307302. Epub 2023 Apr 27. PMID: 37104734

COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review.
Shear SL, Shams K, Weisberg J, Hamidi N, Scott SC. Clin Oncol (R Coll Radiol). 2023 Jul;35(7):e421-e433. doi: 10.1016/j.clon.2023.03.006. Epub 2023 Mar 15. PMID: 37019693

Sociodemographic disparities affect COVID-19 vaccine uptake in non-elderly adults with increased risk of severe COVID-19.
Hedberg P, Sotoodeh A, Askling HH, Nauclér P. J Intern Med. 2023 Jul 9. doi: 10.1111/joim.13700. Online ahead of print. PMID: 37424218

"Fear and anxiety is what I recall the best.": A phenomenological examination of mothers' pregnancy experiences during COVID-19 in the United States.
Huynh T, Boise C, Kihntopf ME, Schaefer AA, Schafer M. Midwifery. 2023 Jul;122:103700. doi: 10.1016/j.midw.2023.103700. Epub 2023 Apr 18. PMID: 37099827

Financial Incentives for COVID-19 Vaccines Among People Experiencing Homelessness.
Rosen AD, Howerton I, Brosnan HK, Stefanescu A, Gomih A, Ngo C, Chang AH, Nguyen A, Thomas EH. Am J Prev Med. 2023 Jul;65(1):12-18. doi: 10.1016/j.amepre.2023.01.020. Epub 2023 Jan 18. PMID: 37074258

Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
Roshchina Y, Rozhkova K, Roshchin S. Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.06.067. Online ahead of print. PMID: 37419852

Vaccine uptake in caregivers family members and patients with dementia and relationship with severity of dementia and caregiver burden: a cross-sectional study.
Lucijanic J, Hanzevacki M, Bazdaric K, Jurin I, Lucijanic M. Aging Clin Exp Res. 2023 Jul;35(7):1565-1569. doi: 10.1007/s40520-023-02443-6. Epub 2023 May 25. PMID: 37227580

Increasing COVID-19 Vaccination Coverage for Newcomer Communities: The Importance of Disaggregation by Language.
Steiner A, Rodrigues KK, Mudenge N, Young J, Rasulo R, Payton C, DeSilva M, Michel J, Fabio M, Yun K. Am J Trop Med Hyg. 2023 Apr 17;109(1):90-93. doi: 10.4269/ajtmh.22-0724. Print 2023 Jul 5. PMID: 37068751

Using the increasing vaccination model and the moderating roles of chronic medical conditions and education to understand COVID-19 vaccination uptake in Singapore.
Chen XK, Ong J, Neo LS, Tan LF. Transl Behav Med. 2023 Jul 1;13(7):453-464. doi: 10.1093/tbm/ibac095. PMID: 37084298

COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour.
Ammitzbøll C, Thomsen MK, Andersen JB, Bartels LE, Hermansen MF, Johannsen AD, Mistegaard CE, Mikkelsen S, Vils SR, Erikstrup C, Hauge EM, Troldborg A. Mod Rheumatol. 2023 Jul 4;33(4):777-785. doi: 10.1093/mr/roac069. PMID: 35860843

Does the Message Frame Promote People's Willingness to Vaccinate when they Worry about Side Effects from the COVID-19 Vaccine? Evidence from an Online Survey Experiment in China.
Li J, Tang Z, Gong Z. Health Commun. 2023 Jul;38(8):1688-1696. doi: 10.1080/10410236.2022.2028469. Epub 2022 Jan 20. PMID: 35057686

Pregnant individuals' information needs and intention to vaccinate their children with routine and COVID-19 vaccines: Findings from a cross-sectional survey.
Vasudevan L, Stinnett SS, Hart L, Gomez Altamirano P, Gonzalez A, Weaver K, Gray B, Bartlett J. Int J Gynaecol Obstet. 2023 Jul;162(1):78-87. doi: 10.1002/ijgo.14571. Epub 2022 Dec 4. PMID: 36353745

Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C, Kragh Thomsen M, Bøgh Andersen J, Jensen JMB, From Hermansen ML, Dahl Johannsen A, Larsen ML, Mistegaard CE, Mikkelsen S, Szabados F, Vils SR, Erikstrup C, Hauge EM, Troldborg A. Rheumatology (Oxford). 2023 Jul 5;62(7):2544-2549. doi: 10.1093/rheumatology/keac666. PMID: 36445008

Hypertension and myocarditis following COVID-19 vaccination. Two sides of the coin?
Angeli F, Reboldi G, Zappa M, Verdecchia P. Eur J Intern Med. 2023 Jul;113:107-109. doi: 10.1016/j.ejim.2023.04.023. Epub 2023 Apr 28. PMID: 37130772

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF, Pang D, Kam KQ, Lye DC, Ong B, Chong CY, Tan KB. Lancet Child Adolesc Health. 2023 Jul;7(7):463-470. doi: 10.1016/S2352-4642(23)00101-3. Epub 2023 May 15. PMID: 37201540

Does COVID-19 vaccine exacerbate rotator cuff symptoms? A prospective study.
İğrek S, Ulusoy İ, Çeliksöz AH. BMC Musculoskelet Disord. 2023 Jul 4;24(1):551. doi: 10.1186/s12891-023-06660-y. PMID: 37403025

Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
Münter R, Sørensen E, Hasselbalch RB, Christensen E, Nielsen SD, Garred P, Ostrowski SR, Bundgaard H, Iversen KK, Andresen TL, Larsen JB. Mol Pharm. 2023 Jul 3;20(7):3356-3366. doi: 10.1021/acs.molpharmaceut.2c01036. Epub 2023 Mar 23. PMID: 36952227

An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.
Wang HY, Qiu L, Ou CY, Lin ZQ, Huang ZD, Chen P, Ma Q, Lu YR, Ran H, Liu WB. Neurol Sci. 2023 Jul;44(7):2239-2245. doi: 10.1007/s10072-023-06811-y. Epub 2023 May 9. PMID: 37160544

Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.
Samandari T, Ongalo JB, McCarthy KD, Biegon RK, Madiega PA, Mithika A, Orinda J, Mboya GM, Mwaura P, Anzala O, Onyango C, Oluoch FO, Osoro E, Dutertre CA, Tan N, Hang SK, Hariharaputran S, Lye DC, Herman-Roloff A, Le Bert N, Bertoletti A. J Clin Invest. 2023 Jul 3;133(13):e170011. doi: 10.1172/JCI170011. PMID: 37219944

Political network composition predicts vaccination attitudes.
Facciani M, Lazić A, Viggiano G, McKay T. Soc Sci Med. 2023 Jul;328:116004. doi: 10.1016/j.socscimed.2023.116004. Epub 2023 Jun 2. PMID: 37295206

Trust in science, medicine and medical providers and its relations to vaccine beliefs: A latent class analysis.

Sanmarchi F, Gibertoni D, Golinelli D, Gori D, Fantini MP, Scheier LM. Scand J Public Health. 2023 Jul;51(5):727-734. doi: 10.1177/14034948221134187. Epub 2022 Nov 9. PMID: 36349530

Social network analysis of COVID-19 vaccine YouTube videos in Odisha, India: mapping the channel network and analyzing comment sentiment.
Alperstein N, Pascual-Ferrá P, Ganjoo R, Bhakktaram A, Burleson J, Barnett DJ, Jamison AM, Kluegel E, Mohanty S, Orton PZ, Parida M, Rath S, Rimal R. BMC Proc. 2023 Jul 7;17(Suppl 7):9. doi: 10.1186/s12919-023-00260-3. PMID: 37420218

Knowledge, Attitude and Practice of Undergraduate Medical Students of Bangladesh Regarding COVID-19 and its Vaccination.
Ahasan F, Nasir M, Perveen RA, Rahman N, Omar E, Akter S, Khanam M, Anny FC, Quadir R, Zahan T, Farha N, Chowdhury AS, Iqbal MJ, Akter MT, Rahman S, Begum T, Sabiha K, Anwar MA. Mymensingh Med J. 2023 Jul;32(3):794-801. PMID: 37391976

Humoral immune response to two doses of COVID-19 mRNA-based vaccines in people living with HIV: A systematic review and meta-analysis.
Farhadian N, Sharifi S, Taghadosi M, Farhadian M, Vaziri S. Rev Med Virol. 2023 Jul;33(4):e2451. doi: 10.1002/rmv.2451. Epub 2023 Apr 18. PMID: 37072909

Association between Covid-19 vaccination and incidence of type 1 diabetes in China: Evidence from 14.14 million registered residents between 2007 and 2021.
Liu C, Guo MN, Chai Z, Xin Z, Chen G, Zimmet PZ, Yang JK. Diabetes Res Clin Pract. 2023 Jul;201:110723. doi: 10.1016/j.diabres.2023.110723. Epub 2023 May 18. PMID: 37209876

Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, Lewin BJ, Kim JS, Shaw SF, Takhar H, Jodar L, Tartof SY. Lancet Infect Dis. 2023 Jul;23(7):806-815. doi: 10.1016/S1473-3099(23)00118-4. Epub 2023 Mar 15. PMID: 36933565

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
Zaloum SA, Wood CH, Tank P, Upcott M, Vickaryous N, Anderson V, Baker D, Chance R, Evangelou N, George K, Giovannoni G, Harding KE, Hibbert A, Ingram G, Jolles S, Kang AS, Loveless S, Moat SJ, Richards A, Robertson NP, Rios F, Schmierer K, Willis M, Dobson R, Tallantyre EC. Mult Scler. 2023 Jul;29(8):979-989. doi: 10.1177/13524585231185247. PMID: 37431627

Assessing the Immunization Information System and electronic health record interface accuracy for COVID-19 vaccinations.
McGreevy S, Murray M, Montero L, Gibson C, Comfort B, Barry M, Kirmer-Voss K, Coy A, Zufer T, Rampon KH, Woodward J. JAMIA Open. 2023 Apr 13;6(2):ooad026. doi: 10.1093/jamiaopen/ooad026. eCollection 2023 Jul. PMID: 37063406

The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury.
Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2088-2099. doi: 10.1016/j.cgh.2022.12.040. Epub 2023 Mar 1. PMID: 36868489

Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era.
Sato T, Umeda M, Sato S, Michitsuji T, Shimizu T, Koga T, Furuse Y, Kawakami A. Clin Immunol. 2023 Jul;252:109656. doi: 10.1016/j.clim.2023.109656. Epub 2023 May 30. PMID: 37263519

New-onset retroperitoneal fibrosis following COVID-19 mRNA vaccination: Coincidental or vaccine-induced phenomenon?
Ture HY, Kim NR, Nam EJ. Int J Rheum Dis. 2023 Jul;26(7):1368-1372. doi: 10.1111/1756-185X.14621. Epub 2023 Feb 22. PMID: 36814401

Status of New Vaccine Introduction - Worldwide, 2016-2021.
Kaur G, Casey RM, Patel JC, Bloem P, Walldorf JA, Hyde TB. MMWR Morb Mortal Wkly Rep. 2023 Jul 7;72(27):746-750. doi: 10.15585/mmwr.mm7227a2. PMID: 37410663

Exploring polyamine interactions and binding pockets in SARS-CoV-2 ORF3a.
Boonamnaj P, Pandey RB, Sompornpisut P. J Mol Graph Model. 2023 Jul;122:108487. doi: 10.1016/j.jmgm.2023.108487. Epub 2023 Apr 10. PMID: 37086515

Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A; Valneva Phase 3 Booster Trial Group. J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.06.022. Online ahead of print. PMID: 37406777

Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis.
Al-Haideri M, Mohammad TAM, Darvishzadehdeldari S, Karbasi Z, Alimohammadi M, Faramarzi F, Khorasani S, Rasouli A, Tahmasebi S, Darvishi M, Akhavan-Sigari R. Int J Rheum Dis. 2023 Jul;26(7):1227-1234. doi: 10.1111/1756-185X.14713. Epub 2023 Jun 12. PMID: 37309305

Leveraging natural language processing and geospatial time series model to analyze COVID-19 vaccination sentiment dynamics on Tweets.
Ye J, Hai J, Wang Z, Wei C, Song J. JAMIA Open. 2023 Apr 12;6(2):ooad023. doi: 10.1093/jamiaopen/ooad023. eCollection 2023 Jul. PMID: 37063408

It was a pleasure to read, "Exploring COVID-19 Vaccine Hesitancy Among Stakeholders in African American and Latinx Communities in the Deep South Through the Lens of the Health Belief Model".
Stubbs AW, Regmi S, Ward KD. Am J Health Promot. 2023 Jul;37(6):874-875. doi: 10.1177/08901171231159474. Epub 2023 Feb 25. PMID: 36840695

Vaccine hesitancy among healthcare workers in low- and middle-income countries during the COVID-19 pandemic: Results from facility surveys across six countries.
Baral P, Ahmed T, Amor Fernandez P, Peters MA, Drouard SHP, Muhoza P, Mwinnyaa G, Mwansambo C, Nzelu C, Tassembedo M, Uddin MH, Wesseh CS, Yansane ML, Bergeron JR, Karibwami AD, Lopez Chicheri TIOZ, Ogunlayi MIA, Sieleunou I, Hashemi T, Hansen PM, Shapira G. PLoS One. 2023 Jul 7;18(7):e0288124. doi: 10.1371/journal.pone.0288124. eCollection 2023. PMID: 37418435

An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.
Tajnur R, Rezwan R, Aziz A, Islam MS. Health Sci Rep. 2023 Jul 2;6(7):e1377. doi: 10.1002/hsr2.1377. eCollection 2023 Jul. PMID: 37404449

[COVID-19 vaccination for people with severe mental diseases : Results of the COVID Ψ outpatient survey and recommendations for psychiatry].
Wiegand HF, Fehr M, Glock M, Rueb M, Roth-Sackenheim C, Köhler S, Pogarell O, Horster S, Geschke K, Tüscher O, Lieb K, Falkai P, Hölzel LP, Adorjan K. Nervenarzt. 2023 Jul;94(7):619-624. doi: 10.1007/s00115-023-01477-5. Epub 2023 May 3. PMID: 37138091

Perceptions of COVID-19 vaccine side effects by political affiliation.
Farabee D, Hawken A. J Public Health (Oxf). 2023 Jul 6:fdad105. doi: 10.1093/pubmed/fdad105. Online ahead of print. PMID: 37414730

Evaluation of Serial Testing After Exposure to COVID-19 in Early Care and Education Facilities, Illinois, March-May 2022.
Holman EJ, Winfield CM, Borkowf CB, Kauerauf J, Baur C, Ahmed S, Funk M, Pinsoneault A, Barnes A, Hutcherson H, Oberholtzer Z, Carter B, Ruth LJ, Thomas ES. Public Health Rep. 2023 Jul-Aug;138(4):664-670. doi: 10.1177/00333549231173014. Epub 2023 May 13. PMID: 37178058

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.
Kanai D, Wakui H, Hanaoka M, Haze T, Azushima K, Shinoda S, Tsukamoto S, Taguchi S, Kinguchi S, Kanaoka T, Toya Y, Hirawa N, Kato H, Watanabe F, Hanaoka K, Mitsuhashi H, Yamaguchi S, Ohnishi T, Tamura K. Clin Exp Nephrol. 2023 Jul;27(7):639-647. doi: 10.1007/s10157-023-02342-0. Epub 2023 Mar 28. PMID: 36977892

Antibody response, neutralizing potency, and transplacental antibody transfer following SARS-CoV-2 infection versus mRNA-1273, BNT162b2 COVID-19 vaccination in pregnancy.
Dude CM, Joseph NT, Forrest AD, Verkerke HP, Cheedarla N, Govindaraj S, Irby LS, Easley KA, Smith AK, Stowell SR, Neish A, Amara RR, Jamieson DJ, Dunlop AL, Badell ML, Velu V. Int J Gynaecol Obstet. 2023 Jul;162(1):154-162. doi: 10.1002/ijgo.14648. Epub 2023 Jan 19. PMID: 36598270

Preliminary results of COVID-19 vaccination among Taiwanese pregnant women: A single-center, prospective, case-control study.
Law KS, Hsu YT, Chen HP. Int J Gynaecol Obstet. 2023 Jul;162(1):133-138. doi: 10.1002/ijgo.14682. Epub 2023 Feb 5. PMID: 36652197

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.
Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Cancer Med. 2023 Jul 6. doi: 10.1002/cam4.6314. Online ahead of print. PMID: 37409608

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P, Cizmeci D, Kwatra G, Izu A, Lee JS, Bertera HL, Fischinger S, Mann C, Amanat F, Wang W, Koen AL, Fairlie L, Cutland CL, Ahmed K, Dheda K, Barnabas SL, Bhorat QE, Briner C, Krammer F,

Saphire EO, Gilbert SC, Lambe T, Pollard AJ, Nunes M, Wuhrer M, Lauffenburger DA, Madhi SA, Alter G. Nat Immunol. 2023 Jul;24(7):1161-1172. doi: 10.1038/s41590-023-01513-1. Epub 2023 Jun 15. PMID: 37322179

Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic.
Star J, Bandi P, Nargis N, Islami F, Yabroff KR, Minihan AK, Smith RA, Jemal A. Cancer Epidemiol Biomarkers Prev. 2023 Jul 5;32(7):879-888. doi: 10.1158/1055-9965.EPI-23-0114. PMID: 37129858

Effects of Covid-19 Vaccination during Pregnancy on the Obstetric and Neonatal Outcomes in a Tertiary Health Care Center.
Tripathy GS, Rath TS, Behera S, Lekha KS, Kar D, Pendyala S. J Mother Child. 2023 Jul 6;27(1):72-78. doi: 10.34763/jmotherandchild.20232701.d-22-00043. eCollection 2023 Jun 1. PMID: 37409659

Addressing sociodemographic disparities in COVID-19 vaccine uptake among youth in Zimbabwe.
Larsson L, Dziva Chikwari C, Simms V, Tembo M, Mahomva A, Mugurungi O, Hayes RJ, Mackworth-Young CRS, Bernays S, Mavodza C, Taruvinga T, Bandason T, Dauya E, Ferrand RA, Kranzer K. BMJ Glob Health. 2023 Jul;8(7):e012268. doi: 10.1136/bmjgh-2023-012268. PMID: 37407229

Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R, Ozbey D, Agbas A, Aksu B, Yildiz N, Uckardes D, Saygili S, Yilmaz EK, Yildirim ZY, Tasdemir M, Kiykim A, Cokugras H, Canpolat N, Nayir A, Kocazeybek B, Caliskan S. Pediatr Nephrol. 2023 Jul;38(7):2199-2208. doi: 10.1007/s00467-022-05813-w. Epub 2022 Dec 2. PMID: 36459243

Experiences of American Health Departments, Health Systems, and Community Organizations in COVID-19 Vaccine Provision for Refugee, Immigrant, and Migrant Communities.
Thomas CM, Yun K, Mudenge NU, Abudiab S, de Acosta D, Fredkove WM, Garcia Y, Hoffman SJ, Karim S, Mann E, Smith MK, Yu K, Dawson-Hahn E. Am J Trop Med Hyg. 2023 Jul 10:tpmd230034. doi: 10.4269/ajtmh.23-0034. Online ahead of print. PMID: 37429571

nCoVDock2: a docking server to predict the binding modes between COVID-19 targets and its potential ligands.
Liu K, Lu X, Shi H, Xu X, Kong R, Chang S. Nucleic Acids Res. 2023 Jul 5;51(W1):W365-W371. doi: 10.1093/nar/gkad414. PMID: 37194703

Herbal supplements as treatment options for COVID-19: A call for clinical development of herbal supplements for emerging and re-emerging viral threats in Sub-Saharan Africa.
Onyeaghala AA, Anyiam AF, Husaini DC, Onyeaghala EO, Obi E. Sci Afr. 2023 Jul;20:e01627. doi: 10.1016/j.sciaf.2023.e01627. Epub 2023 Mar 5. PMID: 36974333

Generalized painful papulovesicular eruption following the COVID-19 BNT162b2 mRNA vaccine.
Lee JM, Lee YS, Lee YJ, Lee JH, Han TY, Choi JE. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e834-e836. doi: 10.1111/jdv.19043. Epub 2023 Mar 23. PMID: 36914917

COVID-19 vaccination uptake in people with epilepsy: Comment.
Kleebayoon A, Wiwanitkit V. Seizure. 2023 Jul;109:18-19. doi: 10.1016/j.seizure.2023.04.018. Epub 2023 Apr 26. PMID: 37178661

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.
Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Xu S, Li J, Liu D, Baidoo AAH, Ibrahim D, Alhaj M, Chen Y, Zhou Q, Xie L. Nat Commun. 2023 Jul 8;14(1):4043. doi: 10.1038/s41467-023-39766-x. PMID: 37422518

COVID-19 vaccination produces exercise-responsive SARS-CoV-2-specific T-cells regardless of infection history.
Smith KA, Zúñiga TM, Baker FL, Batatinha H, Pedlar CR, Burgess SC, Gustafson MP, Katsanis E, Simpson RJ. J Sport Health Sci. 2023 Jul 1:S2095-2546(23)00061-3. doi: 10.1016/j.jshs.2023.06.006. Online ahead of print. PMID: 37399887

Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination.
Steiner S, Schwarz T, Corman VM, Jeworowski LM, Bauer S, Drosten C, Scheibenbogen C, Hanitsch LG. J Clin Immunol. 2023 Jul;43(5):869-881. doi: 10.1007/s10875-023-01468-w. Epub 2023 Mar 17. PMID: 36932291

Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021.
Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Eur J Hosp Pharm. 2023 Jul;30(4):e15. doi: 10.1136/ejhpharm-2021-002933. Epub 2021 Jul 27. PMID: 34315774

The Impact of Priority Settings at the Start of COVID-19 Mass Vaccination on Subsequent Vaccine Uptake in Japan: One-Year Prospective Cohort Study.
Hori D, Takahashi T, Ozaki A, Tabuchi T. JMIR Public Health Surveill. 2023 Jul 10;9:e42143. doi: 10.2196/42143. PMID: 37235691

A panel dataset of COVID-19 vaccination policies in 185 countries.
Cameron-Blake E, Tatlow H, Andretti B, Boby T, Green K, Hale T, Petherick A, Phillips T, Pott A, Wade A, Zha H. Nat Hum Behav. 2023 Jul 6. doi: 10.1038/s41562-023-01615-8. Online ahead of print. PMID: 37414885

Acute vulvar ulcer as a possible adverse event of gene-based COVID-19 vaccines: A review of 14 cases.
Kanetani H, Obuchi T, Ishikawa H, Shozu M. J Obstet Gynaecol Res. 2023 Jul;49(7):1846-1853. doi: 10.1111/jog.15647. Epub 2023 Apr 17. PMID: 37069805

Vaccination against SARS-CoV-2 and its relationship with public interest in mental health: a study between 2020-2022 in Spain.
Becerra-García JA, Barbeito S, Calvo A, Sanchez-Gutierrez T. Psychol Health Med. 2023 Jul;28(6):1460-1469. doi: 10.1080/13548506.2022.2159049. Epub 2022 Dec 18. PMID: 36529938

Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19.
Zysman M, Asselineau J, Saut O, Frison E, Oranger M, Maurac A, Charriot J, Achkir R, Regueme S, Klein E, Bommart S, Bourdin A, Dournes G, Casteigt J, Blum A, Ferretti G, Degano B, Thiébaut R, Chabot F, Berger P, Laurent F, Benlala I. Eur Radiol. 2023 Jul 5. doi: 10.1007/s00330-023-09759-x. Online ahead of print. PMID: 37405504

Thinking about Social Consequences of COVID-19 Influenced Preventive Intention: The Case of South Korea.
Chae J, Jung EH. Health Commun. 2023 Jul;38(8):1563-1571. doi: 10.1080/10410236.2021.2020981. Epub 2022 Jan 4. PMID: 34979829

Management of glioblastoma multiform (GBM) during the SARS-COV-2 pandemic: A review of the literature.
Hajikarimloo B, Fahim F, Sabbagh Alvani M, Oveisi S, Zali A, Anvari H, Oraee-Yazdani S. World Neurosurg. 2023 Jul 8:S1878-8750(23)00722-2. doi: 10.1016/j.wneu.2023.05.094. Online ahead of print. PMID: 37429378

Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.
Day B, Menschik D, Thompson D, Jankosky C, Su J, Moro P, Zinderman C, Welsh K, Dimova RB, Nair N. Pharmacoepidemiol Drug Saf. 2023 Jul;32(7):763-772. doi: 10.1002/pds.5605. Epub 2023 Mar 7. PMID: 36813704

Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting.
van der Boom MDX, van Eekeren R, van Hunsel FPAM. Pharmacoepidemiol Drug Saf. 2023 Jul;32(7):783-794. doi: 10.1002/pds.5610. Epub 2023 Mar 21. PMID: 36919526

Vaccine Hesitancy in India: Facilitators and Inhibitors.
Parveen H, Nasir S, Shahnawaz MG, Husain F, Baig J, Shankar A. Health Educ Behav. 2023 Jul 4:10901981231179503. doi: 10.1177/10901981231179503. Online ahead of print. PMID: 37401790

Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).
Royo-Cebrecos C, Robert-Montaner Ï, Vilanova D, Bailles E, Serrano-Pons J, Valero O, Buldon JM, Bermudez-de-Castro L, Mahia E, Pujadas J, Cobo F, Piqué JM, Albiol S. J Cancer Res Clin Oncol. 2023 Jul;149(7):2883-2892. doi: 10.1007/s00432-022-04141-8. Epub 2022 Jul 9. PMID: 35809113

Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists.
Gupta AK, Talukder M, Rosen T, Piguet V. Am J Clin Dermatol. 2023 Jul;24(4):541-556. doi: 10.1007/s40257-023-00778-4. Epub 2023 Apr 27. PMID: 37106278

Investigation on anti-Corona viral potential of Yarrow tea.
Tilwani K, Patel A, Parikh H, Thakker DJ, Dave G. J Biomol Struct Dyn. 2023 Jul;41(11):5217-5229. doi: 10.1080/07391102.2022.2082532. Epub 2022 May 31. PMID: 35639782

Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.
Labani A, Chou S, Kaviani K, Ropero B, Russman K, Becker D. Mult Scler Relat Disord. 2023 Jul 2;77:104865. doi: 10.1016/j.msard.2023.104865. Online ahead of print. PMID: 37418929

Vaccination in pregnancy: Healthcare provider attitudes and practices.
Rodriguez GF, Vilariño V, Agasse E, St Onge JE, Shafazand S, Potter J. Int J Gynaecol Obstet. 2023 Jul;162(1):58-69. doi: 10.1002/ijgo.14572. Epub 2022 Nov 30. PMID: 36352834

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group. Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02414-4. Online ahead of print. PMID: 37414897

Outcome of COVID-19 infection and the impact of COVID-19 vaccination in chronic kidney disease patients: A single-center study.
Kolla M, Rout NK, Gupta S, Mohapatra SK, Alone VD, Singh P. Ann Afr Med. 2023 Jul-Sep;22(3):347-351. doi: 10.4103/aam.aam_81_22. PMID: 37417024

A comparison of the effect on pain management of two non-pharmacological methods used during administration of Pfizer-BioNTech COVID-19 vaccine (BNT162b2): A randomized controlled study.
Yılmaz D, Kutlu M, Baki E. Jpn J Nurs Sci. 2023 Jul;20(3):e12533. doi: 10.1111/jjns.12533. Epub 2023 Mar 31. PMID: 36999594

Detection of anti-SARS-CoV-2 antibodies in tears: Ocular surface immunity to COVID-19.
Guemes-Villahoz N, Burgos-Blasco B, Echevarria-Torres PL, Vidal-Villegas B, Rodriguez de la Peña A, Diaz-Valle D, Fernández-Vigo JI, Sánchez-Ramón S, Garcia-Feijoo J. Arch Soc Esp Oftalmol (Engl Ed). 2023 Jul;98(7):397-403. doi: 10.1016/j.oftale.2023.05.009. Epub 2023 May 27. PMID: 37247663

Comments on COVID Vaccine Hesitancy and Traffic Crash Risk.
Schabas R, Grant J, Fulford M, Rau N. Am J Med. 2023 Jul;136(7):e146. doi: 10.1016/j.amjmed.2023.02.021. PMID: 37344093

Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines.
Lee J, Woodruff MC, Kim EH, Nam JH. Exp Mol Med. 2023 Jul 10. doi: 10.1038/s12276-023-00999-x. Online ahead of print. PMID: 37430088

Openness buffers the impact of Belief in Conspiracy Theories on COVID-19 vaccine hesitancy: Evidence from a large, representative Italian sample.
Li TY, de Girolamo G, Zamparini M, Malvezzi M, Candini V, Calamandrei G, Starace F, Zarbo C, Götz FM. Pers Individ Dif. 2023 Jul;208:112189. doi: 10.1016/j.paid.2023.112189. Epub 2023 Mar 28. PMID: 37008556

Applying the Hornik & Woolf Approach to Identify Messaging Themes and Improve COVID-19 Vaccine Confidence Among Federally Qualified Health Centers' Workforce in Wisconsin.
Yang S, Shen L, Gregory S, Probst B, Farrar-Edwards D, Passmore SR. J Health Commun. 2023 Jul 7:1-19. doi: 10.1080/10810730.2023.2230929. Online ahead of print. PMID: 37417770

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Woo EJ, Gee J, Marquez P, Baggs J, Abara WE, McNeil MM, Dimova RB, Su JR. Vaccine. 2023 Jul 5;41(30):4422-4430. doi: 10.1016/j.vaccine.2023.06.023. Epub 2023 Jun 14. PMID: 37321898

Frontline healthcare workers' mental health and wellbeing during the first year of the COVID-19 pandemic: Analysis of interviews and social media data.
Vera San Juan N, Martin S, Badley A, Maio L, Gronholm PC, Buck C, Flores EC, Vanderslott S, Syversen A, Symmons SM, Uddin I, Karia A, Iqbal S, Vindrola-Padros C. J Med Internet Res. 2023 Jul 4. doi: 10.2196/43000. Online ahead of print. PMID: 37402283

Responses to a COVID-19 vaccination intervention: Qualitative analysis of 17K unsolicited SMS replies.
Blazek ES, West AB, Bucher A. Health Psychol. 2023 Jul;42(7):496-509. doi: 10.1037/hea0001297. Epub 2023 May 29. PMID: 37253209

Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.
Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Salim B, Ziade N, Velikova T, Gracia-Ramos AE, Kuwana M, Day J, Makol A, Distler O, Chinoy H, Traboco LS, Wibowo SAK, Tehozol EAZ, Serrano JR, García-De La Torre I; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Parodis I. Rheumatology (Oxford). 2023 Jul 5;62(7):2453-2463. doi: 10.1093/rheumatology/keac661. PMID: 36413073

Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine.
Del Saz BS. Eur J Clin Invest. 2023 Jul 3:e14050. doi: 10.1111/eci.14050. Online ahead of print. PMID: 37395096

Bias assessment of a test-negative design study of COVID-19 vaccine effectiveness used in national policymaking.
Graham S, Tessier E, Stowe J, Bernal JL, Parker EPK, Nitsch D, Miller E, Andrews N, Walker JL, McDonald HI. Nat Commun. 2023 Jul 6;14(1):3984. doi: 10.1038/s41467-023-39674-0. PMID: 37414791

Injuries and medical emergencies among international travelers.
Potin M, Carron PN, Genton B. J Travel Med. 2023 Jul 5:taad088. doi: 10.1093/jtm/taad088. Online ahead of print. PMID: 37405992

Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
Goddard K, Donahue JG, Lewis N, Hanson KE, Weintraub ES, Fireman B, Klein NP. Pediatrics. 2023 Jul 1;152(1):e2023061894. doi: 10.1542/peds.2023-061894. PMID: 37278199

Unravelling COVID-19 vaccination attributes worldwide: an extensive review regarding uptake, hesitancy, and future implication.

Ali HT, Ashour Y, Rais MA, Barakat M, Rezeq TA, Sharkawy MM, Lapic M, Soliman ZA, Abdullah A, Allahham A, Abdelaal A, Amer SA, Rohilla R, Mohanty A, Sah R. Ann Med Surg (Lond). 2023 Jun 12;85(7):3519-3530. doi: 10.1097/MS9.0000000000000921. eCollection 2023 Jul. PMID: 37427228

Optic neuritis following COVID-19 vaccination: Do autoimmune diseases play a role?
Pirani V, Pelliccioni P, Carpenè MJ, Nicolai M, Barbotti F, Franceschi A, Mariotti C. Eur J Ophthalmol. 2023 Jul;33(4):NP46-NP50. doi: 10.1177/11206721221118736. Epub 2022 Aug 11. PMID: 35957600

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation.
Gazit S, Saciuk Y, Perez G, Peretz A, Ben-Tov A, Stuart EA, Patalon T. Lancet Microbe. 2023 Jul;4(7):e495-e505. doi: 10.1016/S2666-5247(23)00103-9. Epub 2023 Apr 14. PMID: 37062294

Advances in mRNA vaccines for viral diseases.
Huang Y, Zhu X, Guo X, Zhou Y, Liu D, Mao J, Xiong Y, Deng Y, Gao X. J Med Virol. 2023 Jul;95(7):e28924. doi: 10.1002/jmv.28924. PMID: 37417396

Coronavirus disease 2019 vaccine skin testing and graded challenges in vaccine-hesitant patients.
Heffes-Doon A, Horne N, Okpara C, Akerman M, Fonacier L. Ann Allergy Asthma Immunol. 2023 Jul;131(1):116-117. doi: 10.1016/j.anai.2023.03.034. Epub 2023 Apr 7. PMID: 37031774

A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough.
Bhattacharya M, Alshammari A, Alharbi M, Dhama K, Lee SS, Chakraborty C. Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124893. doi: 10.1016/j.ijbiomac.2023.124893. Epub 2023 May 17. PMID: 37207746

Modelling the COVID-19 pandemic: Focusing on the case of Greece.
Violaris IG, Lampros T, Kalafatakis K, Ntritsos G, Kostikas K, Giannakeas N, Tsipouras M, Glavas E, Tsalikakis D, Tzallas A. Epidemics. 2023 Jul 5;44:100706. doi: 10.1016/j.epidem.2023.100706. Online ahead of print. PMID: 37423142

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.
Adams K, Riddles JJ, Rowley EAK, Grannis SJ, Gaglani M, Fireman B, Hartmann E, Naleway AL, Stenehjem E, Hughes A, Dalton AF, Natarajan K, Dascomb K, Raiyani C, Irving SA, Sloan-Aagard C, Kharbanda AB, DeSilva MB, Dixon BE, Ong TC, Keller J, Dickerson M, Grisel N, Murthy K, Nanez J, Fadel WF, Ball SW, Patel P, Arndorfer J, Mamawala M, Valvi NR, Dunne MM, Griggs EP, Embi PJ, Thompson MG, Link-Gelles R, Tenforde MW. Lancet Reg Health Am. 2023 Jul;23:100530. doi: 10.1016/j.lana.2023.100530. Epub 2023 Jun 14. PMID: 37333688

Emergency preparedness is a healthcare issue: COVID-19 pandemic's influence on attitudes and behaviors among a national sample of parents.
Glauberman G, Zimet G, Michel A, Fontenot HB. J Pediatr Nurs. 2023 Jul-Aug;71:88-94. doi: 10.1016/j.pedn.2023.04.007. Epub 2023 Apr 12. PMID: 37080118

[Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia].
Leonidou Floruß E, Demidova A, Hofmann SC, Balakirski G. Dermatologie (Heidelb). 2023 Jul;74(7):511-519. doi: 10.1007/s00105-023-05152-3. Epub 2023 May 4. PMID: 37140637

Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Geeraerts T, Guilbeau-Frugier C, Garcia C, Memier V, Raposo N, Bonneville F, Gales C, Darcourt J, Voisin S, Ribes A, Piel-Julian M, Bounes F, Albucher JF, Roux FE, Izopet J, Telmon N, Olivot JM, Sié P, Bauer J, Payrastre B, Liblau RS. Neurol Neuroimmunol Neuroinflamm. 2023 May 26;10(4):e200127. doi: 10.1212/NXI.0000000000200127. Print 2023 Jul. PMID: 37236806

ChatGPT and Vaccines: Can AI Chatbots Boost Awareness and Uptake?
Sohail SS, Madsen DØ, Farhat F, Alam MA. Ann Biomed Eng. 2023 Jul 10. doi: 10.1007/s10439-023-03305-y. Online ahead of print. PMID: 37428336

Mushroom β-glucans: application and innovation for food industry and immunotherapy.
Timm TG, Costa TM, Alberton MD, Helm CV, Tavares LBB. Appl Microbiol Biotechnol. 2023 Jul 6. doi: 10.1007/s00253-023-12656-4. Online ahead of print. PMID: 37410138

Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2.
Fattizzo B, Rampi N, Barcellini W. Blood Rev. 2023 Jul;60:101077. doi: 10.1016/j.blre.2023.101077. Epub 2023 Mar 28. PMID: 37029066

The role of community trust for compliance with the Swedish COVID-19 immunisation programme.
Mankell A, Abdelzadeh A. Scand J Public Health. 2023 Jul;51(5):704-710. doi: 10.1177/14034948221145780. Epub 2023 Jan 6. PMID: 36609189

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.
Patel A, Kumar S, Lai L, Chakravarthy C, Valanparambil R, Reddy ES, Gottimukkala K, Bajpai P, Raju DR, Edara VV, Davis-Gardner ME, Linderman S, Dixit K, Sharma P, Mantus G, Cheedarla N, Verkerke HP, Frank F, Neish AS, Roback JD, Davis CW, Wrammert J, Ahmed R, Suthar MS, Sharma A, Murali-Krishna K, Chandele A, Ortlund EA. Structure. 2023 Jul 6;31(7):801-811.e5. doi: 10.1016/j.str.2023.04.010. Epub 2023 May 11. PMID: 37167972

A Call for Health Education Specialists: Addressing Racism Through an Ecological Framework.
Pettit ML, Pember SE. Health Promot Pract. 2023 Jul;24(4):636-641. doi: 10.1177/15248399221088594. Epub 2022 May 7. PMID: 35531899

Development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals.
Yuan F, Chen C, Covaleda LM, Martins M, Reinhart JM, Sullivan DR, Diel DG, Fang Y. mSphere. 2023 Jul 6:e0006723. doi: 10.1128/msphere.00067-23. Online ahead of print. PMID: 37409816

Clinical characteristics of COVID-19 patients infected by the Omicron variants in Macao, China: A cross-sectional study.

Cheong HH, Sio FI, Chan CC, Neng SI, Sam IP, Cheang T, Tou WI, Lei HS, Cheong TF, Lao EPL, Cheong TH, Kuok CU, Lo IL. Health Sci Rep. 2023 Jul 3;6(7):e1361. doi: 10.1002/hsr2.1361. eCollection 2023 Jul. PMID: 37404450

General publics' perception toward COVID-19 vaccines in Afghanistan, 2021.
Hakim MS, Mansoor GF, Walizada AW, Saeed KMI, Naeemi S, Fazil FA. Hum Vaccin Immunother. 2023 Jul 7:2228164. doi: 10.1080/21645515.2023.2228164. Online ahead of print. PMID: 37417006

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022.
Kim JM, Yoo MG, Bae SJ, Kim J, Lee H. J Korean Med Sci. 2023 Jul 10;38(27):e211. doi: 10.3346/jkms.2023.38.e211. PMID: 37431541

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. PMID: 37337616

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data.
Feng S, McLellan J, Pidduck N, Roberts N, Higgins JPT, Choi Y, Izu A, Jit M, Madhi SA, Mulholland K, Pollard AJ, Temple B, Voysey M. EClinicalMedicine. 2023 Jul 1;61:102073. doi: 10.1016/j.eclinm.2023.102073. eCollection 2023 Jul. PMID: 37425373

Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort study.
Docherty AB, Farrell J, Thorpe M, Egan C, Dunn S, Norman L, Shaw CA, Law A, Leeming G, Norris L, Brooks A, Prodan B, MacLeod R, Baxter R, Morris C, Rennie D, Oosthuyzen W, Semple MG, Baillie JK, Pius R, Seth S, Harrison EM, Lone NI. Lancet Digit Health. 2023 Jul;5(7):e446-e457. doi: 10.1016/S2589-7500(23)00051-1. PMID: 37391265

Reverse vaccinology-based prediction of a multi-epitope SARS-CoV-2 vaccine and its tailoring to new coronavirus variants.
Ezzemani W, Kettani A, Sappati S, Kondaka K, El Ossmani H, Tsukiyama-Kohara K, Altawalah H, Saile R, Kohara M, Benjelloun S, Ezzikouri S. J Biomol Struct Dyn. 2023 Jul;41(11):4917-4938. doi: 10.1080/07391102.2022.2075468. Epub 2022 May 13. PMID: 35549819

Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity.
Tan SY, Foo C, Verma M, Hanvoravongchai P, Cheh PLJ, Pholpark A, Marthias T, Hafidz F, Prawidya Putri L, Mahendradhata Y, Giang KB, Nachuk S, Wang H, Lim J, Legido-Quigley H. Soc Sci Med. 2023 Jul;328:116007. doi: 10.1016/j.socscimed.2023.116007. Epub 2023 Jun 2. PMID: 37279639

Reflections From School Communities in Underserved Populations on Childhood COVID-19 Vaccination.
Pulgaron ER, D'Agostino EM, Johnson SB, Ko LK, Drain PK, Duran MC, Keener Mast D, Kay S, Layer MA, Kenworthy T, Dozier A. Pediatrics. 2023 Jul 1;152(Suppl 1):e2022060352M. doi: 10.1542/peds.2022-060352M. PMID: 37394501

"We're kind of on the back burner": Psychological distress and coping among medical social workers during the COVID-19 pandemic.
Lewinson TD, Washington TR, Allen SE, Murphey JM, Onsando WM. Soc Work Health Care. 2023 Jul-Dec;62(6-7):243-262. doi: 10.1080/00981389.2023.2221718. Epub 2023 Jun 12. PMID: 37303230

Vaccine hesitancy among the nursing officers working in a tertiary care hospital, Puducherry - A mixed-method study.
Gopi AP, Ganesh Kumar S, Subitha L, Patel N. Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101300. doi: 10.1016/j.cegh.2023.101300. Epub 2023 May 15. PMID: 37220530

Understanding Vaccination Among Hesitant Adopters of the COVID-19 Vaccine Using the Increasing Vaccination Model.
Moore R, Purvis RS, CarlLee S, Hallgren E, Kraleti S, Willis DE, McElfish PA. J Health Commun. 2023 Jul 3;28(7):458-476. doi: 10.1080/10810730.2023.2224265. Epub 2023 Jul 2. PMID: 37394866

In-Person Instruction and Educational Outcomes of K-8 Students During the COVID-19 Pandemic.
Uthappa DM, Pak J, McGann KA, Brookhart MA, McKinzie K, Abdelbarr M, Cockrell J, Hickerson J, Armstrong S, D'Agostino EM, Weber DJ, Kalu IC, Benjamin DK, Zimmerman KO, Boutzoukas AE; ABC Science Collaborative. Pediatrics. 2023 Jul 1;152(Suppl 1):e2022060352L. doi: 10.1542/peds.2022-060352L. PMID: 37394499

Lessons to Build an Educational Model for Higher Education Institutions Defined as Anchor Institutions to Tackle Public Health Crises: A Pilot Study on COVID-19 Vaccine Hesitancy Among Faculty and Students in Hebert L. College in the Bronx, NY.
Roldós MI, Burt KG, Eubank J. J Hispanic High Educ. 2023 Jul;22(3):276-290. doi: 10.1177/15381927221099091. Epub 2022 Jun 9. PMID: 37323136

The launch of the EU Health Emergency Preparedness and Response Authority (HERA): Improving global pandemic preparedness?
Wouters OJ, Forman R, Anderson M, Mossialos E, McKee M. Health Policy. 2023 Jul;133:104844. doi: 10.1016/j.healthpol.2023.104844. Epub 2023 May 27. PMID: 37269803

Impacts of the COVID-19 pandemic on immunization with pneumococcal vaccines in children and older adults in Brazil.
Novaes JVLC, de Freitas Faria FM, de Bragança BSC, Dos Santos LI. Prev Med. 2023 Jul 7:107602. doi: 10.1016/j.ypmed.2023.107602. Online ahead of print. PMID: 37423475

A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines.
van Balveren L, van Puijenbroek EP, Davidson L, van Hunsel F. Br J Clin Pharmacol. 2023 Jul;89(7):2113-2121. doi: 10.1111/bcp.15678. Epub 2023 Feb 10. PMID: 36717367

Integrated analysis of online signals and insight generation about digital conversations on COVID-19 vaccines in Eastern and Southern Africa: a longitudinal analysis of social listening data.
Sommariva S, Bon HB, De Almeida S, Mote J, Brouwers S, Sani M, Fol N. BMC Proc. 2023 Jul 4;17(Suppl 7):7. doi: 10.1186/s12919-023-00261-2. PMID: 37403116

Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N, Wang T, Zhao Y, Chi H, Yan F, Xia X. Virol Sin. 2023 Jul 7:S1995-820X(23)00083-4. doi: 10.1016/j.virs.2023.07.003. Online ahead of print. PMID: 37423308

Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN, Butcher NJ, Minchin RF, Kaminskas LM. Mol Pharm. 2023 Jul 3;20(7):3494-3504. doi: 10.1021/acs.molpharmaceut.3c00104. Epub 2023 May 31. PMID: 37256791

Analysis of changing United States Practice Advisory guidelines on COVID-19 vaccine uptake in pregnancy.
Rodriguez GF, Vilariño V, Agasse E, Galli J, Potter J. Int J Gynaecol Obstet. 2023 Jul;162(1):185-187. doi: 10.1002/ijgo.14697. Epub 2023 Feb 10. PMID: 36707060

Investigating changes in travel behavior over time in response to the COVID-19 pandemic.
Rostami A, Kamjoo E, Bamney A, Gupta N, Savolainen PT, Zockaie A. Transp Res Part F Traffic Psychol Behav. 2023 Jul;96:133-154. doi: 10.1016/j.trf.2023.06.001. Epub 2023 Jun 7. PMID: 37342650

Pneumococcal carriage among high-risk adults in a country with nonmandatory pneumococcal vaccination during the coronavirus disease 2019 pandemic.
Ngamprasertchai T, Rattanaumpawan P, Kaewkungwal J, Phisalprapa P, Chongtrakool P, Kerdsin A, Luvira V, Thaipadungpanit J, Kajeekul R, Srisompong J, Yincharoen P, Chokephaibulkit K, Lawpoolsri S. J Infect Public Health. 2023 Jul;16(7):1102-1108. doi: 10.1016/j.jiph.2023.05.007. Epub 2023 May 9. PMID: 37220711

Human circulating and tissue-resident memory CD8$^+$ T cells.
Buggert M, Price DA, Mackay LK, Betts MR. Nat Immunol. 2023 Jul;24(7):1076-1086. doi: 10.1038/s41590-023-01538-6. Epub 2023 Jun 22. PMID: 37349380

ChAdOx1 nCoV-19 vaccination generates spike-specific CD8$^+$ T cells in aged mice.
Foster WS, Newman J, Thakur N, Spencer AJ, Davies S, Woods D, Godfrey L, Ross SH, Sharpe HJ, Richard AC, Bailey D, Lambe T, Linterman MA. Immunol Cell Biol. 2023 Jul;101(6):479-488. doi: 10.1111/imcb.12645. Epub 2023 May 6. PMID: 36975169

Diversity of attitudes towards complementary and alternative medicine (CAM) and vaccines: A representative cross-sectional study in France.
Ward JK, Gauna F, Deml MJ, MacKendrick N, Peretti-Watel P. Soc Sci Med. 2023 Jul;328:115952. doi: 10.1016/j.socscimed.2023.115952. Epub 2023 May 3. PMID: 37245262

COVID-19 Vaccine Adverse Event Detection Based on Multi-label Classification with Various Label Selection Strategies.
Chen D, Zhang R. IEEE J Biomed Health Inform. 2023 Jul 7;PP. doi: 10.1109/JBHI.2023.3292252. Online ahead of print. PMID: 37418397

The Effectiveness of Bivalent mRNA Omicron Containing Booster Vaccines Among Patients With Hematological Neoplasms.
Tadmor T, Melamed G, Alapi H, Patalon T, Rokach L. Anticancer Res. 2023 Jul;43(7):3129-3134. doi: 10.21873/anticanres.16485. PMID: 37351996

Two-birds-one-stone approach to combine protein and mRNA vaccines for COVID-19.
Gao GF. Nat Immunol. 2023 Jul;24(7):1056-1057. doi: 10.1038/s41590-023-01539-5. PMID: 37337102

Assessment of immunoglobin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine.
Asmar I, Almahmoud O, Yaseen K, Jamal J, Omar A, Naseef H, Hasan S. Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101330. doi: 10.1016/j.cegh.2023.101330. Epub 2023 Jun 3. PMID: 37293133

Public Preferences for Policies to Promote COVID-19 Vaccination Uptake.
Sookarodee P, Wiwanitkit V. Value Health. 2023 Jul;26(7):1130. doi: 10.1016/j.jval.2022.06.013. Epub 2022 Jul 20. PMID: 35869000

New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome.
Mv P, Auanassova A, Yessirkepov M, Zimba O, Gasparyan AY, Kitas GD, Ahmed S. Clin Rheumatol. 2023 Jul 8. doi: 10.1007/s10067-023-06694-6. Online ahead of print. PMID: 37422611

COVID-19 Vaccination Safety Profiles in Patients with Solid Tumour Cancers: Comment.
Kleebayoon A, Wiwanitkit V. Clin Oncol (R Coll Radiol). 2023 Jul;35(7):483. doi: 10.1016/j.clon.2023.04.008. Epub 2023 May 5. PMID: 37169672

ACUTE MACULAR NEURORETINOPATHY FOLLOWING SARS-CoV-2 VACCINATION.
Afonso MG, Marques JH, Monteiro S, Lume M, Abreu AC, Maia S. Retin Cases Brief Rep. 2023 Jul 1;17(4):438-440. doi: 10.1097/ICB.0000000000001222. PMID: 37364205

Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: update of the literature and patient characterization.
Ginanneschi F, Vinciguerra C, Volpi N, Piscosquito G, Barone P, Rossi A. Immunol Res. 2023 Jul 3. doi: 10.1007/s12026-023-09406-z. Online ahead of print. PMID: 37395901

Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ. Vaccine. 2023 Jul 5;41(30):4431-4437. doi: 10.1016/j.vaccine.2023.06.007. Epub 2023 Jun 12. PMID: 37316409

Reply to Fung et al. on COVID-19 vaccine case-counting window biases overstating vaccine effectiveness.
Lataster R. J Eval Clin Pract. 2023 Jul 4. doi: 10.1111/jep.13892. Online ahead of print. PMID: 37403424

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
Wang F, Huang B, Deng Y, Zhang S, Liu X, Wang L, Liu Q, Zhao L, Tang L, Wang W, Wang X, Ye F, Hu W, Yang H, Wang S, Ren J, Liu X, Wang C, Guan X, Wang R, Zheng Y, Zhang X, Zheng H, Wu D, An Z, Xu W, Rodewald LE, Gao GF, Yin Z, Tan W. BMC Med. 2023 Jul 3;21(1):233. doi: 10.1186/s12916-023-02942-3. PMID: 37400857

A survey of patient and public perceptions and awareness of SARS-CoV-2-related risks among participants in India and South Africa.
Mbamalu O, Surendran S, Nampoothiri V, Bonaconsa C, Edathadathil F, Zhu N, Carter V, Lambert H, Tarrant C, Ahmad R, Brink A, Steenkamp E, Holmes A, Singh S, Charani E, Mendelson M. PLOS Glob Public Health. 2023 Jul 10;3(7):e0001078. doi: 10.1371/journal.pgph.0001078. eCollection 2023. PMID: 37428718

Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
Mercadal S, Gomez CA, Lee CJ, Couriel DR. Ann Hematol. 2023 Jul;102(7):1837-1843. doi: 10.1007/s00277-023-05131-7. Epub 2023 May 29. PMID: 37246975

COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation.
Sanomachi T, Sumiyoshi Okuma H, Yonemori K. Int Cancer Conf J. 2023 Feb 20;12(3):216-219. doi: 10.1007/s13691-023-00598-7. eCollection 2023 Jul. PMID: 36843626

Enantioselective Effect of Chiral Small Molecules in SARS-CoV-2 Vaccine-Induced Immune Response.
Zhou Z, Zhang Y, Ji H, Jin Y, Chen S, Duan P, Liu Y. Angew Chem Int Ed Engl. 2023 Jul 10;62(28):e202301085. doi: 10.1002/anie.202301085. Epub 2023 Jun 1. PMID: 37163203

Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations.
Ahmed El-Arabey A, Abdalla M, Rashad Abd-Allah A, Marenga HS, Modafer Y, Aloufi AS. Saudi J Biol Sci. 2023 Jul;30(7):103699. doi: 10.1016/j.sjbs.2023.103699. Epub 2023 Jun 3. PMID: 37292255

Comment on the effectiveness of four SARS-COV-2 vaccines.
Kleebayoon A, Wiwanitkit V. Aten Primaria. 2023 Jul;55(7):102655. doi: 10.1016/j.aprim.2023.102655. Epub 2023 May 1. PMID: 37209622

The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study.
Smoll NR, Al Imam MH, Shulz C, Booy R, Khandaker G. Med J Aust. 2023 Jul 3. doi: 10.5694/mja2.52019. Online ahead of print. PMID: 37400415

Evaluation of autoantibody profile in healthy subjects after mRNA vaccination against COVID-19.
Fiorelli D, Caruso V, Belardi R, Bernardini S, Nuccetelli M. Int Immunopharmacol. 2023 Jul 3;122:110592. doi: 10.1016/j.intimp.2023.110592. Online ahead of print. PMID: 37413933

Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies.

Doneddu PE, Briani C, Cocito D, Manganelli F, Fabrizi GM, Matà S, Mazzeo A, Fazio R, Benedetti L, Luigetti M, Inghilleri M, Ruiu E, Siciliano G, Cosentino G, Marfia GA, Carpo M, Filosto M, Antonini G, Notturno F, Sotgiu S, Cucurachi L, Dell'Aquila C, Bianchi E, Rosso T, Giordano A, Fernandes M, Campagnolo M, Peci E, Spina E, Tagliapietra M, Sperti M, Gentile L, Strano C, Germano F, Romozzi M, Moret F, Zarbo IR, Viola DV, Vegezzi E, Mataluni G, Cotti-Piccinelli S, Leonardi L, Carta A, Nobile-Orazio E; INCLUSIVE Study Group. Eur J Neurol. 2023 Jul;30(7):1907-1918. doi: 10.1111/ene.15811. Epub 2023 Apr 11. PMID: 37000158

Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.
Gromowski GD, Cincotta CM, Mayer S, King J, Swafford I, McCracken MK, Coleman D, Enoch J, Storme C, Darden J, Peel S, Epperson D, McKee K, Currier JR, Okulicz J, Paquin-Proulx D, Cowden J, Peachman K. EBioMedicine. 2023 Jul 4;94:104683. doi: 10.1016/j.ebiom.2023.104683. Online ahead of print. PMID: 37413891

Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management.
Barreiro-Pérez M, Pastor Pueyo P, Raposeiras-Roubín S, Montero Corominas D, Uribarri A, Eiros Bachiller R, Rozado Castaño J, García-Cuenllas Álvarez L, Serratosa Fernández L, Domínguez F, Pascual Figal D. Rev Esp Cardiol (Engl Ed). 2023 Jul;76(7):555-563. doi: 10.1016/j.rec.2023.01.011. Epub 2023 Mar 11. PMID: 36914023

Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics.
Broketa M, Sokal A, Mor M, Canales-Herrerias P, Perima A, Meola A, Fernández I, Iannascoli B, Chenon G, Vandenberghe A, Languille L, Michel M, Godeau B, Gallien S, Melica G, Backovic M, Rey FA, Baudry J, Freund NT, Mahévas M, Bruhns P. JCI Insight. 2023 Jul 10;8(13):e166602. doi: 10.1172/jci.insight.166602. PMID: 37252802

CENTRAL RETINAL VEIN OCCLUSION FOLLOWING BNT162B2 (PFIZER-BIONTECH) COVID-19 MESSENGER RNA VACCINE.
Shah PP, Gelnick S, Jonisch J, Verma R. Retin Cases Brief Rep. 2023 Jul 1;17(4):441-444. doi: 10.1097/ICB.0000000000001214. PMID: 35025191

The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
Li Z, Hu Y, Zou B. J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.06.011. Online ahead of print. PMID: 37400016

Menstrual cycle changes after COVID-19 vaccination or infection: not two sides of the same coin.
Laganà AS, Lukanovič D, Noventa M, Margioula-Siarkou C, Terzic S, Chiantera V. Evid Based Nurs. 2023 Jul;26(3):110-111. doi: 10.1136/ebnurs-2022-103613. Epub 2023 Feb 17. PMID: 36804196

Mycophenolic Acid Exposure Determines Antibody Formation Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study.
Meziyerh S, Bouwmans P, van Gelder T, van der Helm D, Messchendorp L, van der Boog PJM, de Fijter JW, Moes DJAR, de Vries APJ; RECOVAC Collaborators. Clin Pharmacol Ther. 2023 Jul;114(1):118-126. doi: 10.1002/cpt.2872. Epub 2023 Mar 14. PMID: 36789469

Commentary on "Characterization of otologic symptoms appearing after COVID-19 vaccination".
Aldè M, Zanetti D, Pignataro L, Cantarella G. Am J Otolaryngol. 2023 Jul-Aug;44(4):103924. doi: 10.1016/j.amjoto.2023.103924. Epub 2023 May 5. PMID: 37163959

Optimizing the Cas13 antiviral train: cargo and delivery.
Sharma S, Myhrvold C. EMBO Mol Med. 2023 Jul 10;15(7):e17146. doi: 10.15252/emmm.202217146. Epub 2023 May 25. PMID: 37231981

Spontaneous suprachoroidal haemorrhage in haemophilia coincident with ChAdOx1 nCoV-19 vaccine.
Behera G, Jossy A, Deb AK, Neelakandan S, Basavarajegowda A. Eur J Ophthalmol. 2023 Jul;33(4):NP59-NP61. doi: 10.1177/11206721221098207. Epub 2022 Apr 28. PMID: 35484818

T follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults.
Boyd MAA, Carey Hoppe A, Kelleher AD, Munier CML. Immunol Cell Biol. 2023 Jul;101(6):504-513. doi: 10.1111/imcb.12635. Epub 2023 Mar 23. PMID: 36825370

Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J, Hainz P, Kryštofová J, Roubalová K, Šťastná-Marková M, Vaníková Š, Musil J, Vydra J, Němečková Š. Leuk Res. 2023 Jul;130:107314. doi: 10.1016/j.leukres.2023.107314. Epub 2023 May 16. PMID: 37216792

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients.
Pommerolle P, Laurent P, Presne C, Brazier F, Jaureguy M, Poulain C, Flahaut G, Mazouz H, Brochot E, Choukroun G, Fourdinier O. Adv Ther. 2023 Jul 1. doi: 10.1007/s12325-023-02580-4. Online ahead of print. PMID: 37392339

Nanovectorization of Ivermectin to avoid overdose of drugs.
Duverger E, Herlem G, Picaud F. J Biomol Struct Dyn. 2023 Jul;41(10):4272-4285. doi: 10.1080/07391102.2022.2066020. Epub 2022 Apr 26. PMID: 35470771

Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience.
Trisolini SM, Capria S, Artoni A, Mancini I, Biglietto M, Gentile G, Peyvandi F, Testi AM. Haematologica. 2023 Jul 1;108(7):1957-1959. doi: 10.3324/haematol.2022.282311. PMID: 36579445

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination.
DeSilva MB, Haapala J, Vazquez-Benitez G, Boyce TG, Fuller CC, Daley MF, Getahun D, Hambidge SJ, Lipkind HS, Naleway AL, Nelson JC, Vesco KK, Weintraub ES, Williams JTB, Zerbo O, Kharbanda EO. Obstet Gynecol. 2023 Jul 1;142(1):125-129. doi: 10.1097/AOG.0000000000005241. Epub 2023 May 9. PMID: 37167612

Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines.

Wang CW, Chen CB, Lu CW, Chen WT, Hui RC, Chiu TM, Chi MH, Lin JC, Huang YH, Chang YC, Wu J, Chen KY, Lin YY, Ger TY, Lin JY, Tsai WT, Pan YJ, Chung WH. J Autoimmun. 2023 Jul;138:103054. doi: 10.1016/j.jaut.2023.103054. Epub 2023 May 15. PMID: 37245259

Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine.
Russo R, Capurro N, Cozzani E, Gasparini G, Canepa P, Parodi A. Int J Dermatol. 2023 Jul;62(7):847-849. doi: 10.1111/ijd.16695. Epub 2023 Apr 26. PMID: 37185976

Torque teno virus viral load predicts SARS-CoV-2 vaccine response in kidney transplant recipients.
Solis M, Benotmane I, Gallais F, Caillard S, Fafi-Kremer S. J Med Virol. 2023 Jul;95(7):e28936. doi: 10.1002/jmv.28936. PMID: 37404001

How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics?
Abduljalil JM, Elghareib AM, Samir A, Ezat AA, Elfiky AA. Int J Biol Macromol. 2023 Jul 1;242(Pt 4):125153. doi: 10.1016/j.ijbiomac.2023.125153. Epub 2023 Jun 1. PMID: 37268078

Purification processes of polymeric nanoparticles: How to improve their clinical translation?
Tehrani SF, Bharadwaj P, Chain JL, Roullin VG. J Control Release. 2023 Jul 6:S0168-3659(23)00421-2. doi: 10.1016/j.jconrel.2023.06.038. Online ahead of print. PMID: 37422123

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK - ERRATUM.
Hadley L, Karachaliou Prasinou A, Christensen H, Ramsay M, Trotter C. Epidemiol Infect. 2023 Jul 6;151:e108. doi: 10.1017/S095026882300105X. PMID: 37409902

College students' influence on COVID-19 vaccination uptake among seniors in China: a protocol of combined cross-sectional and experimental study.
Bian J, Guo Z, Zhang W, Li X, Sun C, Xu X, Zou H. BMC Public Health. 2023 Jul 10;23(1):1322. doi: 10.1186/s12889-023-16209-2. PMID: 37430252

From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
Pelletier C, Labbé F, Bettinger JA, Curran J, Graham JE, Greyson D, MacDonald NE, Meyer SB, Steenbeek A, Xu W, Dubé È. Vaccine. 2023 Jul 5;41(30):4384-4391. doi: 10.1016/j.vaccine.2023.06.002. Epub 2023 Jun 6. PMID: 37302965

Comment on immunity to COVID-19 vaccination in patients with liver disease and transplant recipients.
Kleebayoon A, Wiwanitkit V. Hepatol Commun. 2023 Jun 22;7(7):e00189. doi: 10.1097/HC9.0000000000000189. eCollection 2023 Jul 1. PMID: 37347228

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.
Szebeni J, Kiss B, Bozó T, Turjeman K, Levi-Kalisman Y, Barenholz Y, Kellermayer M. ACS Nano. 2023 Jul 7. doi: 10.1021/acsnano.2c11904. Online ahead of print. PMID: 37417667

Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.
Sutandhio S, Furukawa K, Kurahashi Y, Marini MI, Effendi GB, Hasegawa N, Ishimaru H, Nishimura M, Arii J, Mori Y. J Infect Public Health. 2023 Jul;16(7):1064-1072. doi: 10.1016/j.jiph.2023.05.004. Epub 2023 May 6. PMID: 37196370

Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses.
Vu MN, Pilkington EH, Lee WS, Tan HX, Davis TP, Truong NP, Kent SJ, Wheatley AK. Adv Healthc Mater. 2023 Jul;12(17):e2202595. doi: 10.1002/adhm.202202595. Epub 2023 Feb 24. PMID: 36786027

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo.
Tsuji M, Nair MS, Masuda K, Castagna C, Chong Z, Darling TL, Seehra K, Hwang Y, Ribeiro ÁL, Ferreira GM, Corredor L, Coelho-Dos-Reis JGA, Tsuji Y, Mori M, Boon ACM, Diamond MS, Huang Y, Ho DD. Nat Commun. 2023 Jul 5;14(1):3959. doi: 10.1038/s41467-023-39738-1. PMID: 37402814

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E. J Cancer Res Clin Oncol. 2023 Jul;149(7):3075-3080. doi: 10.1007/s00432-022-04185-w. Epub 2022 Jul 22. PMID: 35867203

Ionizable lipids penetrate phospholipid bilayers with high phase transition temperatures: perspectives from free energy calculations.
Ermilova I, Swenson J. Chem Phys Lipids. 2023 Jul;253:105294. doi: 10.1016/j.chemphyslip.2023.105294. Epub 2023 Mar 31. PMID: 37003484

[Covid-19 vaccines, Di Bella therapy, alternative medicine and the "experts": who to believe?].
Bruzzi P. Recenti Prog Med. 2023 Jul-Aug;114(7):403-406. doi: 10.1701/4062.40457. PMID: 37392101

Allel K, Peters A, Conejeros J, Martínez JRW, Spencer-Sandino M, Riquelme-Neira R, Rivas L, Rojas P, Orellana Chea C, García P, Araos R, McGovern O, Patel TS, Arias CA, Lessa FC, Undurraga EA, Munita JM. Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S20-S28. doi: 10.1093/cid/ciad151. PMID: 37406053

Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes.
Jia X, Dong F, Pyle L, Michels AW, Yu L, Rewers M. Diabetes Technol Ther. 2023 Jul;25(7):492-496. doi: 10.1089/dia.2023.0016. Epub 2023 Apr 12. PMID: 36989496

SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
Abduljaleel Z, Melebari S, Athar M, Dehlawi S, Udhaya Kumar S, Aziz SA, Dannoun AI, Malik SM, Thasleem J, George Priya Doss C. Cell Signal. 2023 Jul 7:110798. doi: 10.1016/j.cellsig.2023.110798. Online ahead of print. PMID: 37423342

Optimization of Vaccine Responses in Solid Organ Transplant Recipients.
Miller-Handley H, Huaman MA. Clin Pharmacol Ther. 2023 Jul;114(1):26-28. doi: 10.1002/cpt.2909. Epub 2023 May 11. PMID: 37170690

Risk of herpes zoster ophthalmicus after COVID-19 vaccination in a large US healthcare claims database.
Akpandak I, Sechrist SJ, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR. Am J Ophthalmol. 2023 Jul 7:S0002-9394(23)00283-0. doi: 10.1016/j.ajo.2023.07.004. Online ahead of print. PMID: 37423396

Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination.
Vogrig A, Versace S, Gigli GL, Fabris M, Honnorat J, Valente M. J Neurol. 2023 Jul;270(7):3289-3293. doi: 10.1007/s00415-023-11723-0. Epub 2023 Apr 28. PMID: 37117736

Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study.
Svensson ALL, Emborg HD, Bartels LE, Ellingsen T, Adelsten T, Cordtz R, Dreyer L, Obel N. Ann Rheum Dis. 2023 Jul 6:ard-2023-223974. doi: 10.1136/ard-2023-223974. Online ahead of print. PMID: 37414519

Differences in reporting of adverse drug reactions due to COVID-19 vaccines depending on the reporter.
Pardo-Cabello AJ, Manzano-Gamero V, Luna JD. Eur J Intern Med. 2023 Jul;113:104-106. doi: 10.1016/j.ejim.2023.03.020. Epub 2023 Mar 22. PMID: 36966066

Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses.
Deshpande A, Schormann N, Piepenbrink MS, Martinez Sobrido L, Kobie JJ, Walter MR. FEBS J. 2023 Jul;290(13):3422-3435. doi: 10.1111/febs.16777. Epub 2023 Apr 4. PMID: 37014961

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity.
Dourdouna MM, Tatsi EB, Syriopoulou V, Michos A. Diagn Microbiol Infect Dis. 2023 Jul;106(3):115948. doi: 10.1016/j.diagmicrobio.2023.115948. Epub 2023 Mar 30. PMID: 37094435

Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021.
Payen SH, Gorzalski A, Siao DD, Pandori M, Verma SC, Rossetto CC. Infect Genet Evol. 2023 Jul;111:105434. doi: 10.1016/j.meegid.2023.105434. Epub 2023 Apr 13. PMID: 37059256

Continuity of Trust: Health Systems' Role in Advancing Health Equity Beyond the COVID-19 Pandemic.
Adekunle TB, Ringel JV, Williams MS, Faherty LJ. Community Health Equity Res Policy. 2023 Jul 3:2752535X231185221. doi: 10.1177/2752535X231185221. Online ahead of print. PMID: 37400357

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose.
Bladh O, Marking U, Havervall S, Norin NG, Aguilera K, Hober S, Smed-Sörensen A, Gordon M, Blom K, Åberg M, Klingström J, Thålin C. Lancet Microbe. 2023 Jul;4(7):e488. doi: 10.1016/S2666-5247(23)00102-7. Epub 2023 Apr 20. PMID: 37086736

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.

Pinder CL, Jankovic D, Fox TA, Kirkwood A, Enfield L, Alrubayyi A, Touizer E, Ford R, Pocock R, Shin JS, Ziegler J, Thomson KJ, Ardeshna KM, Peppa D, McCoy LE, Morris EC. Br J Haematol. 2023 Jul 4. doi: 10.1111/bjh.18962. Online ahead of print. PMID: 37402627

[Inflammation of BCG Inoculation Site Scar after the First Dose of an Anti-SARS-CoV-2 mRNA Vaccine].
Barros Rodrigues J, Pacheco M, Antunes I, Sousa R. Acta Med Port. 2023 Jul 3;36(7-8):511-514. doi: 10.20344/amp.16971. Epub 2022 Sep 19. PMID: 36121099

Correspondence on SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
Kleebayoon A, Wiwanitkit V. Clin Lung Cancer. 2023 Jul;24(5):e161. doi: 10.1016/j.cllc.2023.03.010. Epub 2023 Mar 21. PMID: 37088613

Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago.
Messmer SE, Elmes AT, Jimenez AD, Murphy AL, Guzman M, Watson DP, Poorman E, Mayer S, Infante AF, Keller EG, Whitfield K, Jarrett JB. J Subst Use Addict Treat. 2023 Jul;150:209054. doi: 10.1016/j.josat.2023.209054. Epub 2023 Apr 23. PMID: 37088399

Predictive factors of delayed viral clearance of asymptomatic Omicron-related COVID-19 screened positive in patients with cancer receiving active anticancer treatment.
Lee VH, Chan SK, Tam YH, Chau TC, Chan JFW, Chan SY, Ip CY, Choi HC, Ng SC, Yuen KK. Int J Infect Dis. 2023 Jul;132:40-49. doi: 10.1016/j.ijid.2023.04.397. Epub 2023 Apr 16. PMID: 37072051

Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults.
Hyams C, Qian G, Nava G, Challen R, Begier E, Southern J, Lahuerta M, Nguyen JL, King J, Morley A, Clout M, Maskell N, Jodar L, Oliver J, Ellsbury G, McLaughlin JM, Gessner BD, Finn A, Danon L, Dodd JW; Avon CAP Research Group. J R Soc Med. 2023 Jul 5:1410768231184162. doi: 10.1177/01410768231184162. Online ahead of print. PMID: 37404021

Kinetics of SARS-CoV-2 Serum Antibodies Through the Alpha, Delta, and Omicron Surges Among Vaccinated Health Care Workers at a Boston Hospital.
Dodge MC, Ye L, Duffy ER, Cole M, Gawel SH, Werler MM, Daghfal D, Andry C, Kataria Y. Open Forum Infect Dis. 2023 May 17;10(7):ofad266. doi: 10.1093/ofid/ofad266. eCollection 2023 Jul. PMID: 37396669

Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: how does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
Bayhan Gİ, Güner R, Yahşi A, Özkul A. J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.07.001. Online ahead of print. PMID: 37414158

Coevolution based immunoinformatics approach considering variability of epitopes to combat different strains: A case study using spike protein of SARS-CoV-2.
Mishra SK, Priya P, Rai GP, Haque R, Shanker A. Comput Biol Med. 2023 Jul 1;163:107233. doi: 10.1016/j.compbiomed.2023.107233. Online ahead of print. PMID: 37422941

Predictive Factors of Mortality in Patients with Severe COVID-19 Treated in the Intensive Care Unit: A Single-Center Study in Vietnam.

Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Thi-Kim T, Nguyen-Quang T, Tran-Ngoc-Anh T, Nguyen-Van-Hoai N, Do-Thi-Thu M, Nguyen-Chi T, Nguyen-Van T, Tang-Thi-Thao T, Nguyen-Tuan A, Nguyen-Hoang Q, Hoang-Phi-Tuyet P, Vu-Van G, Nguyen-Lan H, Nguyen-Hong C, Dinh-Ngoc S, Truong-Viet D, Nguyen-Nhu V, Nguyen-Duy T. Pulm Ther. 2023 Jul 7. doi: 10.1007/s41030-023-00231-1. Online ahead of print. PMID: 37415031

Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications.
Jeong M, Lee Y, Park J, Jung H, Lee H. Adv Drug Deliv Rev. 2023 Jul 7:114990. doi: 10.1016/j.addr.2023.114990. Online ahead of print. PMID: 37423563

Overlap of disorders of gut-brain interaction: a systematic review and meta-analysis.
Fairlie T, Shah A, Talley NJ, Chey WD, Koloski N, Yeh Lee Y, Gwee KA, Jones MP, Holtmann G. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):646-659. doi: 10.1016/S2468-1253(23)00102-4. Epub 2023 May 18. PMID: 37211024

This Fall's COVID-19 Vaccines Will Target Omicron XBB Subvariants, but Who Needs Them Remains to Be Seen.
Rubin R. JAMA. 2023 Jul 5. doi: 10.1001/jama.2023.10053. Online ahead of print. PMID: 37405757

Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.
Dai YC, Lin YC, Ching LL, Tsai JJ, Ishikawa K, Tsai WY, Chen JJ, Nerurkar VR, Wang WK. Microbiol Spectr. 2023 Jul 10:e0408122. doi: 10.1128/spectrum.04081-22. Online ahead of print. PMID: 37428104

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus.
Kang M, Kim S, Park JS, Seok HY. Neurol Sci. 2023 Jul;44(7):2247-2249. doi: 10.1007/s10072-023-06715-x. Epub 2023 Mar 1. PMID: 36856906

Before blaming SARS-CoV-2 vaccination for unexpected death from atrial myocarditis, rule out alternative pathophysiologies.
Finsterer J. Leg Med (Tokyo). 2023 Jul;63:102266. doi: 10.1016/j.legalmed.2023.102266. Epub 2023 May 5. PMID: 37196570

Coronavirus disease 2019 vaccines: challenges of using global mass vaccination to achieve herd immunity.
Bao P, Gong J, Mu M, Que Y, Hu P, Luo J, Chang C, Xu G. Chin Med J (Engl). 2023 Jul 5;136(13):1627-1629. doi: 10.1097/CM9.0000000000002270. PMID: 36806245

Long COVID: answers emerge on how many people get better.
Marshall M. Nature. 2023 Jul;619(7968):20. doi: 10.1038/d41586-023-02121-7. PMID: 37369791

Evidence from UK Research Ethics Committee members on what makes a good research ethics review, and what can be improved.
Sidaway M, Collett C, Kolstoe SE. PLoS One. 2023 Jul 3;18(7):e0288083. doi: 10.1371/journal.pone.0288083. eCollection 2023. PMID: 37399215

SARS-CoV-2 vaccination in paediatric patients with epilepsy: experience of a tertiary center in Colombia.
Ortiz-de la Rosa JS, Ramón-Gómez JL, Martínez-Córdoba N, Lince-Rivera I. Rev Neurol. 2023 Jul 1;77(1):13-18. doi: 10.33588/rn.7701.2023127. PMID: 37365720

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro.
Zhou L, Li C, Zhang R, Li Q, Sun Y, Feng Y, Lan T, Ma J. Virol Sin. 2023 Jul 3:S1995-820X(23)00079-2. doi: 10.1016/j.virs.2023.06.010. Online ahead of print. PMID: 37406816

Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England.
Wilde H, Tomlinson C, Mateen BA, Selby D, Kanthimathinathan HK, Ramnarayan P, Du Pre P, Johnson M, Pathan N, Gonzalez-Izquierdo A, Lai AG, Gurdasani D, Pagel C, Denaxas S, Vollmer S, Brown K; CVD-COVID-UK/COVID-IMPACT consortium. BMJ. 2023 Jul 5;382:e073639. doi: 10.1136/bmj-2022-073639. PMID: 37407076

The present evidence summary of SARS-CoV-2 vaccine-associated liver injury: A rapid systematic review.
Li Z, Hu Y, Jiang Y. J Hepatol. 2023 Jul;79(1):e42-e46. doi: 10.1016/j.jhep.2023.02.038. Epub 2023 Mar 9. PMID: 36906108

Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.
Baba A, Tokunaga T, Sakasegawa K, Kanekura T, Tsubouchi H. Eur J Cancer. 2023 Jul;187:96-98. doi: 10.1016/j.ejca.2023.03.036. Epub 2023 Apr 30. PMID: 37130465

A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens.
Joubert S, Stuible M, Lord-Dufour S, Lamoureux L, Vaillancourt F, Perret S, Ouimet M, Pelletier A, Bisson L, Mahimkar R, Pham PL, L Ecuyer-Coelho H, Roy M, Voyer R, Baardsnes J, Sauvageau J, St-Michael F, Robotham A, Kelly J, Acel A, Schrag JD, El Bakkouri M, Durocher Y. Biotechnol Bioeng. 2023 Jul;120(7):1746-1761. doi: 10.1002/bit.28387. Epub 2023 Mar 29. PMID: 36987713

Comment on "immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab".
Mungmunpuntipantip R, Wiwanitkit V. Clin Exp Med. 2023 Jul;23(3):955. doi: 10.1007/s10238-022-00883-4. Epub 2022 Sep 2. PMID: 36053341

Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, Tan KB. Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13. PMID: 36924786

Omicron variant-specific serological imprinting following BA.1 or BA.4/5 bivalent vaccination and previous SARS-CoV-2 infection: A cohort study.
Baerends EAM, Reekie J, Andreasen SR, Stærke NB, Raben D, Nielsen H, Petersen KT, Johansen IS, Lindvig SO, Madsen LW, Wiese L, Iversen MB, Benfield T, Iversen KK, Larsen FD, Andersen SD, Juhl AK,

Dietz LL, Hvidt AK, Ostrowski SR, Krause TG, Østergaard L, Søgaard OS, Lundgren J, Tolstrup M. Clin Infect Dis. 2023 Jul 1:ciad402. doi: 10.1093/cid/ciad402. Online ahead of print. PMID: 37392436

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies.
Feng S, Lin E, Cowling BJ. Lancet Reg Health Am. 2023 Jul;23:100548. doi: 10.1016/j.lana.2023.100548. Epub 2023 Jun 28. PMID: 37397875

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
Wilkins D, Langedijk AC, Lebbink RJ, Morehouse C, Abram ME, Ahani B, Aksyuk AA, Baraldi E, Brady T, Chen AT, Chi H, Choi EH, Cohen R, Danilenko DM, Gopalakrishnan V, Greenough A, Heikkinen T, Hosoya M, Keller C, Kelly EJ, Kragten-Tabatabaie L, Martinón-Torres F, de Los Santos AHM, Nunes MC, Palomino MA, Papenburg J, Pernica JM, Richmond P, Stein RT, Tuffy KM, Verwey C, Esser MT, Tabor DE, Bont LJ; INFORM-RSV Study Group. Lancet Infect Dis. 2023 Jul;23(7):856-866. doi: 10.1016/S1473-3099(23)00062-2. Epub 2023 Mar 17. PMID: 36940703

In silico identification of D449-0032 compound as a putative SARS-CoV-2 M^{pro} inhibitor.
Philippsen GS, Seixas FAV. J Biomol Struct Dyn. 2023 Jul 9:1-8. doi: 10.1080/07391102.2023.2234045. Online ahead of print. PMID: 37424215

Major classes of neutralizing antibodies evaded by the SARS-CoV-2 Omicron variant.
Yuan M, Wilson IA. Structure. 2023 Jul 6;31(7):755-757. doi: 10.1016/j.str.2023.06.005. PMID: 37419097

Humoral Response After Five Successive Doses of SARS-CoV-2 mRNA Vaccine in Kidney Transplant Patients.
Cazorla JM, Villanego F, Aguilera A, Garcia T, Orellana C, Trujillo T, Gómez AM, Mazuecos A. Transplantation. 2023 Jul 1;107(7):e188-e189. doi: 10.1097/TP.0000000000004628. Epub 2023 May 12. PMID: 37170412

SARS-CoV-2 vaccination status and adverse events among patients with psoriasis-Data from the German Registries PsoBest and CoronaBest.
Valencia López MJ, Meineke A, Stephan B, Rustenbach SJ, Kis A, Thaçi D, Mrowietz U, Reich K, Staubach-Renz P, von Kiedrowski R, Bogena H, Augustin M. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e831-e833. doi: 10.1111/jdv.19039. Epub 2023 Mar 27. PMID: 36914370

Doctor launches legal challenge over GMC's failure to investigate fellow medic's covid vaccine claims.
Iacobucci G, Kmietowicz Z. BMJ. 2023 Jul 6;382:p1568. doi: 10.1136/bmj.p1568. PMID: 37414425

Letter to the Editor on "New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine".
Kim S, Eun MY, Seok HY. Am J Phys Med Rehabil. 2023 Jul 1;102(7):e102. doi: 10.1097/PHM.0000000000002208. Epub 2023 Feb 8. PMID: 36762834

Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients.

Ramos L, Hernández-Porto M, Carrillo-Palau M, Alonso-Abreu I, Reygosa C, Hernandez-Guerra M. Inflamm Bowel Dis. 2023 Jul 5;29(7):1165-1169. doi: 10.1093/ibd/izac228. PMID: 36321900

Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases.
Kawazoe M, Aoki K, Hirose W, Masuoka S, Nanki T. Eur J Intern Med. 2023 Jul;113:111-113. doi: 10.1016/j.ejim.2023.04.008. Epub 2023 Apr 10. PMID: 37045711

Psychosocıal Perspectıve And Suggestıons On The Penal Executıon System In The Pandemıc: The Case Of Turkey.
Nergiz H. Turk Psikiyatri Derg. 2023 Summer;34(2):140-142. doi: 10.5080/u26946. PMID: 37357902

High Burden of Intestinal Colonization With Antimicrobial-Resistant Bacteria in Chile: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.
Araos R, Smith RM, Styczynski A, Sánchez F, Acevedo J, Maureira L, Paredes C, González M, Rivas L, Spencer-Sandino M, Peters A, Khan A, Sepulveda D, Wettig LR, Rioseco ML, Usedo P, Soto PR, Huidobro LA, Ferreccio C, Park BJ, Undurraga E, D'Agata EMC, Jara A, Munita JM. Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S75-S81. doi: 10.1093/cid/ciad283. PMID: 37406045

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Cancer Immunol Immunother. 2023 Jul 10. doi: 10.1007/s00262-023-03489-1. Online ahead of print. PMID: 37428196

Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study.
Ishiguro C, Mimura W, Uemura Y, Maeda M, Murata F, Fukuda H. Open Forum Infect Dis. 2023 May 18;10(7):ofad274. doi: 10.1093/ofid/ofad274. eCollection 2023 Jul. PMID: 37404955

Lessons from UK historical cohort studies of lower respiratory tract infections - Authors' reply.
Collaro AJ, McElrea MS, Perret JL, Dharmage SC, Chang AB. Lancet Child Adolesc Health. 2023 Jul;7(7):e15. doi: 10.1016/S2352-4642(23)00130-X. PMID: 37349021

Repurposing the Medicines for Malaria Venture's COVID Box to discover potent inhibitors of Toxoplasma gondii, and in vivo efficacy evaluation of almitrine bismesylate (MMV1804175) in chronically infected mice.
Dos Santos BR, Ramos ABDSB, de Menezes RPB, Scotti MT, Colombo FA, Marques MJ, Reimão JQ. PLoS One. 2023 Jul 7;18(7):e0288335. doi: 10.1371/journal.pone.0288335. eCollection 2023. PMID: 37418497

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.
Abdul Aziz N, Nash SG, Zaidi A, Nyberg T, Groves N, Hope R, Lopez Bernal J, Dabrera G, Thelwall S. J Infect. 2023 Jul;87(1):e8-e11. doi: 10.1016/j.jinf.2023.04.015. Epub 2023 Apr 24. PMID: 37100176

Author Response: SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.

Baars AE, Van Doorn PA, Jacobs BC, Kuitwaard K. Neurology. 2023 Jul 4;101(1):51. doi: 10.1212/WNL.0000000000207541. PMID: 37400258

Reader Response: SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
Harth CE. Neurology. 2023 Jul 4;101(1):50-51. doi: 10.1212/WNL.0000000000207542. PMID: 37400257

Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.
Caserta MT, O'Leary ST, Munoz FM, Ralston SL; COMMITTEE ON INFECTIOUS DISEASES. Pediatrics. 2023 Jul 1;152(1):e2023061803. doi: 10.1542/peds.2023-061803. PMID: 37357729

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
Carr EJ, Wu MY, Gahir J, Harvey R, Townsley H, Bailey C, Fowler AS, Dowgier G, Hobbs A, Herman L, Ragno M, Miah M, Bawumia P, Smith C, Miranda M, Mears HV, Adams L, Haptipoglu E, O'Reilly N, Warchal S, Sawyer C, Ambrose K, Kelly G, Beale R, Papineni P, Corrah T, Gilson R, Gamblin S, Kassiotis G, Libri V, Williams B, Swanton C, Gandhi S, Lv Bauer D, Wall EC; Crick COVID Serology Consortium. Lancet Infect Dis. 2023 Jul;23(7):781-784. doi: 10.1016/S1473-3099(23)00289-X. Epub 2023 Jun 5. PMID: 37290472

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230701:20230710 as the publication date 52 records*

1.20230210983VACCINE COMBINATION AGAINST SARS-COV-2 AND METHOD FOR PREVENTING INFECTION OF SARS-COV-2
US - 06.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18149482 Solicitante CHANCE BIOTECHNOLOGY, INC. Inventor/a Li-Kuang CHEN
A vaccine combination against SARS-CoV-2 includes a primer vaccine composition and a booster vaccine composition. The primer vaccine composition includes an effective amount of an Alphacoronavirus, and the primer vaccine is a live vaccine. The booster vaccine composition includes an effective amount of a Betacoronavirus, and the booster vaccine is a live vaccine.

2.20230210985VARICELLA ZOSTER VIRUS VACCINE
US - 06.07.2023
Clasificación Internacional A61K 39/25 Nº de solicitud 18145136 Solicitante MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH Inventor/a Hyo Jung NAM
The present invention relates to a vaccine composition for prevention or treatment of chicken pox or *Herpes zoster*, the vaccine composition comprising a surface protein (gE) of *Varicella zoster* Virus and especially an aluminum salt as an adjuvant. The vaccine composition according to the present invention employs a protein antigen, thus showing greater outstanding stability than a live vaccine and has an optimized mixture ratio of adjuvants to elicit effective antibody induction, thereby being useful as a vaccine for preventing or treating *Varicella zoster* Virus-caused chicken pox or *Herpes zoster.*

3.WO/2023/125741METHOD FOR ASSESSING QUALITY OF VACCINE AND PROTECTION DURATION OF VACCINE
WO - 06.07.2023
Clasificación Internacional G01N 27/626 Nº de solicitud PCT/CN2022/143102 Solicitante BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO., LTD. Inventor/a MA, Qingwei
A method for assessing the quality of a vaccine and the protection duration of the vaccine. Body fluids of the human body before and after vaccination are measured by means of MALDI-TOF MS mass spectrometry, and immune response fingerprint spectra consisting of 5-200 mass spectrum peaks are acquired respectively. A model classifier is created on the basis of changes between the spectrum from before an immune response and the spectrum from after the immune response with the combination of a machine learning method, and molecular immune changes of a human serum sample to be measured are analyzed, so as to determine whether the sample is vaccinated and an immune protection effect is generated, thus assessing the quality of the vaccine and/or the protection duration of the vaccine. Meanwhile, changes of various molecular immune responses in the body fluids can be measured. In addition to ensuring high specificity, the accuracy and sensitivity of measurement are effectively increased, experiment operations are simplified, the measurement time is reduced, and measurement costs are reduced.

4.20230213248PORTABLE INSULIN AND VACCINE STORAGE DEVICE
US - 06.07.2023
Clasificación Internacional F25B 21/04 Nº de solicitud 18181592 Solicitante Pranay Wal Inventor/a Pranay Wal
The present disclosure relates to a portable insulin and vaccine storage device. The portable insulin and vaccine storage device comprises of a storage unit to store insulin and vaccine; a Peltier module for heating or cooling the storage unit; a heat sink capable of working as a heat exchanger to maintain temperature of the Peltier module; a radiator and fan for maintaining temperature of the storage unit; a control unit for controlling functioning of the portable insulin and vaccine storage device; and a power supply unit for powering the portable insulin and vaccine storage device. The present disclosure provides a device designed to function under extreme weather conditions and being affordable, it is poised to bring about a positive change in the life of people afflicted with diabetes in South Asian countries and those who need to store insulin.

5.WO/2023/123164METHOD FOR EVALUATING QUALITY OF VACCINE AND DURATION OF VACCINE PROTECTION
WO - 06.07.2023
Clasificación Internacional G01N 33/68 Nº de solicitud PCT/CN2021/142888 Solicitante BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO., LTD. Inventor/a MA, Qingwei
A method for evaluating the quality of a vaccine and the duration of vaccine protection. Body fluids before and after vaccination in a human body are detected by means of an MALDI-TOF MS technique to respectively obtain immune response fingerprint spectra composed of 5-200 mass spectrum peaks. On the basis of the changes in the fingerprint spectra of immune responses that do not occur and immune responses that occur, a model classifier is established in combination with a machine learning method to analyze the immune changes of molecules in a human serum sample to be detected, so that whether the sample is vaccinated and an immune protection effect is generated can be judged, so as to evaluate the quality of the vaccine and/or the duration of vaccine protection. Changes in the immune responses of multiple molecules in body fluids can be simultaneously detected, and the method for simultaneously monitoring multiple immune marker molecules breaks through the traditional idea of monitoring a single marker such as a neutralizing antibody. On the basis of ensuring high specificity, the accuracy and

sensitivity of detection are effectively improved, the experimental operation is simplified, the detection time is shortened, and the detection cost is reduced.

6.4205759GEFLÜGELADENOVIRUS-UNTEREINHEITSIMPFSTOFF UND VERFAHREN ZU SEINER HERSTELLUNG
EP - 05.07.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 22150211 Solicitante VETERINAERMEDIZINISCHE UNIV WIEN Inventor/a HESS MICHAEL
The present invention provides a fowl adenovirus (FAdV) subunit vaccine, comprising at least a chimeric FAdV fiber protein and an adjuvant. This vaccine may be used to ameliorate or prevent adenoviral gizzard erosion (AGE), inclusion body hepatitis (IBH) or hepatitis-hydropericardium syndrome (HHS) in birds. The invention further relates to a method of producing an FAdV subunit vaccine, comprising the steps of expressing a chimeric FAdV fiber protein in an expression system, purifying the fiber protein, and combining the fiber protein with an adjuvant to obtain the FAdV subunit vaccine.

7.WO/2023/128672NOVEL VACCINIA VIRUS VARIANT WITH INCREASED EXTRACELLULAR ENVELOPED VIRUS PRODUCTION
WO - 06.07.2023
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/KR2022/021646 Solicitante THE ASAN FOUNDATION Inventor/a SON, Woo-Chan
The present invention relates to a vaccinia virus with increased extracellular enveloped virus production, and the like. The vaccinia virus of the present invention improves intratumoral virus spread by increasing the production of extracellular enveloped virus related to viral transmission, thereby maximizing the oncolytic potential of vaccinia virus, and thus is expected to exhibit a significantly high anticancer effect compared to conventional vaccinia viruses.

8.4206215AUF EBV ABZIELENDER ALLOGENER B-ZELLEN-IMPFSTOFF UND HERSTELLUNGSVERFAHREN DAFÜR
EP - 05.07.2023
Clasificación Internacional C07K 14/05 Nº de solicitud 21846257 Solicitante WEST CHINA HOSPITAL OF SICHUAN UNIV Inventor/a YANG HANSHUO
The invention belongs to the field of biotechnology, and relates to an allogeneic B cell vaccine against various human-susceptible viruses and a preparation method therefor. The vaccine has anti-tumor and/or anti-viral preventive and/or therapeutic effects. Specifically, the present invention provides a B cell composition, wherein comprising an allogeneic B cell and a virus antigen, the B cell composition is irradiated with a certain dose of ionizing irradiation. The present invention also provides a B cell vaccine, comprising the above B cell composition. The invention also provides a preparation method for the B cell vaccine and a method and system for improving the antigen presentation ability of the B cell.

9.20230210967IMPROVED PEPTIDE VACCINE
US - 06.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17996866 Solicitante BRIGHTPATH BIOTHERAPEUTICS CO., LTD. Inventor/a Yukie SASAKURA
A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.

10.WO/2023/126882DENV EDIII-NS1 CONSENSUS SEQUENCE-BASED DENGUE DNA VACCINE
WO - 06.07.2023

Clasificación Internacional A61K 39/12 Nº de solicitud PCT/IB2022/062891 Solicitante NATIONAL CENTRE FOR BIOLOGICAL SCIENCES Inventor/a KRISHNA, Sudhir
The present invention relates to relates to a DNA vaccine construct against Dengue virus. In particular, the present disclosure relates to a DENV (dengue) DNA vaccine construct, comprising at least one antigenic regions of envelope domain and at least one protein-coding region. The present disclosure also relates to a process for constructing a DNA vaccine construct and uses thereof.

11.WO/2023/123696N PROTEIN EPITOPE MUTATION MARKER FOR PREPARING PRRSV GENOTYPE II EPITOPE-DELETED VACCINE STRAIN AND USE THEREOF
WO - 06.07.2023
Clasificación Internacional C07K 14/08 Nº de solicitud PCT/CN2022/081330 Solicitante LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES Inventor/a ZHANG, Jing
The present invention provides an N protein epitope mutation marker for preparing a PRRSV genotype II epitope-deleted vaccine strain and a use thereof, pertaining to the technical field of biological products. The mutation marker mutates one or multiple amino acids on the basis of the epitope sequence of positions 92-103 at the C-terminal of a PRRSV genotype II N protein, and the amino acid sequence of the epitope mutation marker is as shown in SEQ ID NO: 1, X1 being T, P, or A, and X2 being V or A. By identifying a dominant antigen epitope in the PRRSV genotype II virus N protein, the present invention proves that after the epitope is deleted, a naturally infected animal and an animal immunized with an epitope-deleted whole virus inactivated vaccine or an attenuated vaccine can be effectively distinguished, providing a basis for preparation of a PRRSV immune clearance, prevention and control product.

12.WO/2023/125974MRNA VACCINE
WO - 06.07.2023
Clasificación Internacional C07K 14/08 Nº de solicitud PCT/CN2022/144148 Solicitante GUANGZHOU NATIONAL LABORATORY Inventor/a PENG, Hua
Provided is a mRNA vaccine, said mRNA vaccine containing an immune cell targeting molecule that is expressed in fusion with an antigen and enhances the immunological effectiveness of a mRNA vaccine.

13.WO/2023/128051CHIMERIC VIRUS EXPRESSING PORCINE PRODUCTIVE AND RESPIRATORY SYNDROME VIRUS-DERIVED PEPTIDE AND VACCINE COMPOSITION COMPRISING SAME
WO - 06.07.2023
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/KR2022/001653 Solicitante BIOPOA, INC. Inventor/a CHA, Sang Ho
Provided are a chimeric virus expressing a porcine reproductive and respiratory syndrome virus (PRRSV)-derived peptide and a use thereof as a vaccine. The chimeric virus has an excellent immune stimulating effect and is useful as a vaccine that can effectively protect against PRRSV by suppressing viral amplification in target cells.

14.4205761NEUES REKOMBINANTES SPIKE-PROTEIN DES CORONAVIRUS, POLYNUKLEOTID, VEKTOR MIT POLYNUKLEOTID UND IMPFSTOFF ZUR VORBEUGUNG ODER BEHANDLUNG EINER CORONAVIRUSINFEKTION MIT VEKTOR
EP - 05.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21862123 Solicitante CELLID CO LTD Inventor/a KANG CHANG-YUIL
The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is

stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.

15.WO/2023/123175METHOD FOR EVALUATING WHETHER INDIVIDUAL COMPLETES VACCINATION OR INDIVIDUAL IMMUNE CHANGES
WO - 06.07.2023
Clasificación Internacional G01N 33/569 Nº de solicitud PCT/CN2021/142937 Solicitante BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO., LTD. Inventor/a MA, Qingwei
A method for evaluating whether an individual completes vaccination or human immune changes after vaccination. The human body fluid before and after vaccination is detected by means of MALDI-TOF MS mass spectrometry, and fingerprint spectra before and after immune response each composed of 5-200 mass spectrum peaks can be obtained respectively. On the basis of changes in the fingerprint spectra before and after immune response, a model classifier is established in combination with a machine learning method, the molecular immune change in a human serum sample to be detected is analyzed, whether said sample is inoculated with a vaccine and an immune protection effect is generated can be determined, and therefore the vaccine quality and/or the duration of protection of the vaccine are evaluated. According to the method, changes in various molecular immune responses in the human body fluid can be detected simultaneously. The detection accuracy and the sensitivity are effectively improved on the basis of ensuring high specificity.

16.20230210987ADJUVANT AND VACCINE CONTAINING ADJUVANT
US - 06.07.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 18119973 Solicitante The University of Tokyo Inventor/a Yoshihiro KAWAOKA
The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.

17.WO/2023/129867EXPRESSION OF EIMERIA SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
WO - 06.07.2023
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/US2022/082240 Solicitante APPLIED BIOTECHNOLOGY INSTITUTE, INC. Inventor/a HOWARD, John
Vaccines and methods of expressing a polypeptide of *Eimeria* are provided in which a protective response to *Eimeria* is produced when administered to an animal. The vaccine provides for expression of *Eimeria* vaccine proteins 3-1e, Gam82, and/or EF-1a polypeptide in a plant or plant part, linked to a promoter preferentially directing expression to embryo tissue of the plant or plant part. Further embodiments provide that the polypeptide may be targeted to the apoplast/cell wall or the endoplasmic reticulum. Increased expression levels in the plant or plant part are obtained. The plant or plant materials in an embodiment may be orally administered.

18.20230210981CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE

US - 06.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18001116 Solicitante The Wistar Institute of Anatomy and Biology Inventor/a David Weiner
Disclosed herein is a vaccine comprising a Coronavirus disease 2019 (COVID-19) antigen in a combination with an immunoglobulin from post-exposure treatment. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

19.WO/2023/124116VACCINE ADJUVANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 06.07.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/113087 Solicitante CHENGDU MAXVAX BIOTECHNOLOGY LLC Inventor/a CHEN, Dexiang
A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21: 50 μg/ml to 300 μg/ml; (2) Poly I:C: 400 μg/mL to 3000 μg/mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

20.20230210982AUTOLOGOUS DENDRITIC CELL VACCINE KIT AND USES
US - 06.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18061045 Solicitante AIVITA BIOMEDICAL, INC Inventor/a Gabriel NISTOR
Disclosed herein is a kit to produce a personalized vaccine based on autologous dendritic cells. The kit contains all the materials, reagents and information necessary to produce a dose of live dendritic cell vaccine against a pathogen organism, part of a pathogen organism, a toxin, a venom, a structure obtained by recombinant method or chemical synthesis.

21.WO/2023/123517CIRCRNA VACCINE AGAINST INFECTIOUS SPLEEN AND KIDNEY NECROSIS VIRUS, AND A CONSTRUCTION METHOD THEREFOR AND THE USE THEREOF
WO - 06.07.2023
Clasificación Internacional C12N 15/62 Nº de solicitud PCT/CN2021/144066 Solicitante SOOCHOW UNIVERSITY Inventor/a GONG, Chengliang
The present invention relates to a circRNA vaccine against an infectious spleen and kidney necrosis virus, and a construction method therefor and the use thereof. The method comprises: synthesizing a fusion sequence P-IRES-m6A-MCP with an in-vitro T7 (or S6) transcription promoter, an internal ribosome entry site IRES of an encephalomyocarditis virus, an N6-methyladenine (m6A) site, and an open reading frame of a major capsid protein (MCP) of an infectious spleen and kidney necrosis virus (ISKNV) sequentially at a 5' end, subjecting RNA to in-vitro transcription with a T7 (or S6) transcriptase by using P-IRES-m6A-MCP as a template, removing the DNA template with DNaseI, then performing linkage and cyclization with a T4 RNA ligase, removing linear RNA with a RNase R, and then obtaining circular RNA, i.e. circRNA-MCP. By means of the immunization with the circRNA-MCP, the incidence of infectious spleen and kidney necrosis can be reduced.

22.4203997IMPFSTOFFPLATTFORM
EP - 05.07.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21819196 Solicitante PECSI TUDOMANYEGYETEM Inventor/a TAPODI ANTAL
The invention relates to a vaccine platform, comprising a lipid binding amino acid sequence and an oligomerization sequence. In particular, the lipid binding amino acid sequence and an oligomerization sequence are derived from filensin, a protein with no or minimal immunogenicity. Filensin has an extremely

strong membrane binding capacity and oligomerization property, making it an ideal carrier for an antigenic moiety. An immunization platform comprising a nucleic acid sequence(s) coding for a lipid binding amino acid sequence and an oligomerization sequence is also provided.

23.4203996FÜNFWERTIGER IMPFSTOFF GEGEN NEISSERIA MENINGITIDIS MIT EINEM SYNTHETISCHEN MENA-ANTIGEN
EP - 05.07.2023
Clasificación Internacional A61K 39/095 Nº de solicitud 21769663 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a ADAMO ROBERTO
The inventors have identified a combined vaccine for immunisation against bacterial meningitis caused by multiple pathogens.

24.20230210979ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES
US - 06.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17996727 Solicitante Greffex, Inc. Inventor/a Uwe D. STAERZ
A vaccine for preventing β-CoV infection includes at least one viral vector containing a β-CoV DNA sequence which codes the S protein for the β-CoV. The β-CoV RNA sequence can be a SARS-2 β-CoV DNA sequence. The vaccine may further includes a packaging plasmid based on an adenovirus. The viral vector and packaging plasmid can be contained in a packaging cell and encapsidated in a capsid. A method of vaccinating a mammal subject against infection from at least one group of β-CoV includes separating a broad group of β-CoV into homology groups based on similarities in the β-CoV RNA sequences which code for their S proteins, identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group, and preparing a viral vector including at least a portion of the consensus sequence from at least one homology group.

25.WO/2023/126536VACCINE RECOMMENDATION METHOD IMPLEMENTED BY A COMPUTER SYSTEM
WO - 06.07.2023
Clasificación Internacional G16H 20/10 Nº de solicitud PCT/EP2023/050011 Solicitante SYADEM Inventor/a KOECK, Jean-Louis
The invention relates to a vaccine recommendation method (1), implemented by a computer system (2) comprising a set of vaccination rules (VS1) and at least one digital interface (NT1), comprising the following steps: providing at least one set of health data of at least one person by means of said digital interface (NT1); determining at least one set of vaccination recommendations by an inference engine (IM1) from said provided set of health data and said set of vaccination rules (VS1); and transmitting said set of recommendations to said digital interface (NT1).

26.20230212230INFLUENZA VIRUS PRODUCTION METHOD USING SINGLE-USE CULTURE PROCESS SYSTEM AND RAPID CONFIRMATION TEST OF INFLUENZA VIRUS ANTIGEN PURIFICATION CONDITION
US - 06.07.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17922262 Solicitante SK BIOSCIENCE CO., LTD. Inventor/a Hwan-ui JUNG
The present invention relates to an influenza virus production method using a disposable culture process system, and a test for quickly checking conditions for influenza virus antigen purification. According to the present invention, conditions for influenza surface antigen obtainment (purification) may be quickly and reliably checked according to the unique method of the present invention, even without using the single radial immunodiffusion technique which is conventionally used as a standard test method when producing

influenza vaccines, and thus the production time for an influenza surface antigen subunit vaccine is notably reduced, thereby enabling quick response as a result of rapid vaccine development/manufacturing, even in a rapid novel influenza pandemic situation. In addition, according to the influenza virus production method of the present invention, culture media exchange may be carried out in an airtight system by using a continuous low-speed centrifuge using a disposable bag, and thus the possibility of contamination occurring during the virus production process may be greatly reduced.

27.20230212574CONSTRUCT OF SELF-CIRCULARIZATION RNA
US - 06.07.2023
Clasificación Internacional C12N 15/113 Nº de solicitud 18045860 Solicitante Rznomics Inc. Inventor/a Seong-Wook LEE
A self-circularization RNA construct that can be expressed in a DNA vector and simultaneously circularized through a self-targeting and splicing reaction to form a circRNA is disclosed. The circRNA can consist only of a gene of interest which can be a coding, non-coding, or a combination thereof. The gene of interest has the advantage of being able to rapidly express a peptide or protein. The formed circRNA has a circular structure and has a stable and high half-life because 5' and 3' ends are not exposed. Accordingly, functional RNA such as miRNA, anti-miRNA, siRNA, shRNA, aptamer, functional RNA for gene/RNA editing, ADAR (adenosine deaminase acting on the RNA)-recruiting RNA, mRNA vaccine, mRNA therapeutic agent, vaccine adjuvant, and CAR-T mRNA can be produced as a stable circRNA in cells.

28.20230212186CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
US - 06.07.2023
Clasificación Internacional C07D 403/12 Nº de solicitud 18068195 Solicitante Nurix Therapeutics, Inc. Inventor/a Arthur T. SANDS
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

29.4203994ZUBEREITUNGEN MIT VERBESSERTEM IMMUNGEDÄCHTNIS UND VERWENDUNGEN DAVON
EP - 05.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21862881 Solicitante TORIGEN PHARMACEUTICALS INC Inventor/a SUCKOW MARK
Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation/preparations may comprise a target infectious agent protein/peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide/protein antigen or peptide or fragment thereof).

30.WO/2023/126343MRNA VACCINE AGAINST VARIANTS OF SARS-COV-2
WO - 06.07.2023

Clasificación Internacional A61K 39/215 Nº de solicitud PCT/EP2022/087715 Solicitante FONDO RICERCA MEDICA S.R.L. Inventor/a RIPOSATI, Andrea
A SARS-CoV-2 vaccine composition is described, having a specific set of mutations in the spike protein sequence.

31.WO/2023/125749METHOD FOR EVALUATING WHETHER INDIVIDUAL COMPLETES VACCINATION OR INDIVIDUAL IMMUNE CHANGE
WO - 06.07.2023
Clasificación Internacional G01N 33/68 Nº de solicitud PCT/CN2022/143141 Solicitante BEIJING YIXINBOCHUANG BIOTECHNOLOGY CO., LTD. Inventor/a MA, Qingwei
A method for evaluating whether an individual completes vaccination or immune changes in an inoculated human. The body fluid of a human body before and after a vaccination is detected by means of an MALDI-TOF MS mass spectrometry technology to respectively obtain immune response fingerprint spectra composed of 5-200 mass spectrometry peaks; a model classifier is established on the basis of the difference between the fingerprint spectrum when an immune response does not occur and that when an immune response occurs combined with a machine learning method, so as to analyze the immune change of molecules in a human serum sample to be detected, whereby it is possible to determine whether the sample is vaccinated and has an immune protection effect, thus evaluating the quality of the vaccine and/or the expiration date of the vaccine protection. The change of various molecular immune responses in body fluid can be detected at the same time, the traditional idea of monitoring a single marker, such as a neutralizing antibody, is broken, on the basis of ensuring high specificity, the detection accuracy and sensitivity are effectively improved, the experimental operation is simplified, the detection time is shortened, and the detection cost is reduced.

32.20230210965PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT
US - 06.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18068514 Solicitante CureVac SE Inventor/a Mariola FOTIN-MLECZEK
The present invention relates to novel prime-boost regimens that involve the administration of at least one mRNA construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen. The present invention further describes methods, uses, vaccination compositions, kits and packaged vaccine components related to or useful for one or more of such regimens

33.20230210968RIBONUCLEOPROTEIN APPROACH TO BOOST THE STING SIGNALING FOR CANCER IMMUNOTHERAPY
US - 06.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18001161 Solicitante MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor/a Paula HAMMOND
Disclosed herein is a non-covalent complex, comprising: a tetramer of a recombinant protein; and an agonist of a Stimulator of Interferon Gene (STING) protein or a pharmaceutically acceptable salt thereof, wherein the recombinant protein comprises a STING protein lacking a transmembrane domain (STINGΔTM protein). Additionally, provided is a vaccine composition, comprising a non-covalent complex and a pharmaceutically acceptable carrier, wherein the non-covalent complex comprises: a recombinant protein

comprising a STINGΔTM protein and a tumor epitope; and an agonist of a STING protein or a pharmaceutically acceptable salt thereof. Further provided are methods of treating and preventing cancer using the disclosed complexes, pharmaceutical compositions, and vaccines.

34.WO/2023/123722ANTI-CORONAVIRUS POLYPEPTIDE, AND DERIVATIVES THEREOF AND APPLICATION THEREOF
WO - 06.07.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2022/084473 Solicitante INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES Inventor/a GAO, Fu
Provided is an anti-coronavirus polypeptide, and on this basis, cholesterol-containing derivatives of the polypeptide are provided. These polypeptide derivatives yield an unexpected inhibitory effect on coronaviruses, and in particular prototype strains and variant strains of SARS-CoV-2, can be used for preparing a drug or vaccine for preventing or treating novel coronavirus, and has a great prevention or treatment potential.

35.3194652VACCINES AND COMPOSITIONS BASED ON SARS-COV-2 S PROTEIN
CA - 10.07.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 3194652 Solicitante GUANGZHOU RIBOBIO CO., LTD. Inventor/a ZHANG, BILL BILIANG
This disclosure provides vaccines and compositions based on SARS-CoV-2 S protein, and specifically relates to recombinant SARS-CoV-2 spike protein (S protein) and mRNA and DNA coding thereof. This disclosure also relates to recombinant plasmid comprising DNA sequence encoding recombinant S protein. This disclosure further relates to composition comprising the recombinant S protein and/or mRNA mentioned above, mRNA-carrier particle such as lipid nanoparticle (LNP), and composition such as a vaccine composition.

36.20230212529ATTENUATED VARIANT OF THE RIFT VALLEY FEVER VIRUS, COMPOSITION COMPRISING SAME, AND USES THEREOF
US - 06.07.2023
Clasificación Internacional C12N 7/00 Nº de solicitud 18000558 Solicitante INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA (INIA) Inventor/a Alejandro BRUN TORRES
The invention relates to an attenuated variant of the Rift Valley Fever Virus (RVFV) with mutations in the amino acid sequence coded by segments L, M and S of RVFV RNA; a pharmaceutical or veterinary composition comprising same; an attenuated RVFV variant for use in the prevention of Rift Valley Fever; and a vaccine against Rift Valley Fever comprising the attenuated RVFV variant. Attenuated RVFV variants with the mutations Gly924Ser and Ala303Thr in protein L, and the Pro82Leu substitution in protein NSs, are also included.

37.4204001IMPFSTOFF GEGEN HUMANES CYTOMEGALOVIRUS
EP - 05.07.2023
Clasificación Internacional A61K 39/295 Nº de solicitud 21862650 Solicitante MODERNATX INC Inventor/a KRAMARCZYK JACK F
Aspects of the disclosure relate to methods for producing an antigen- specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.

38.4207209VERFAHREN ZUR IMPFEMPFEHLUNG, DAS VON EINEM COMPUTERSYSTEM DURCHGEFÜHRT WIRD
EP - 05.07.2023
Clasificación Internacional G16H 20/10 Nº de solicitud 22150073 Solicitante SYADEM Inventor/a KOECK JEAN-LOUIS

L'invention concerne un procédé de recommandation vaccinale (1), mis en œuvre par un système informatique (2) comprenant un ensemble de règles de vaccination (VS1) et au moins une interface numérique (NT1), comprenant les étapes suivantes : fourniture d'au moins un ensemble de données de santé d'au moins une personne au moyen de ladite interface numérique (NT1) ; détermination d'au moins un ensemble de recommandations de vaccination par un moteur d'inférence (IM1) à partir dudit ensemble de données de santé fourni et dudit ensemble règles de vaccination (VS1) ; transmission dudit ensemble de recommandations sur ladite interface numérique (NT1).

39.4206225ANTI-MALARIA-PARASITEN-ANTIKÖRPER
EP - 05.07.2023
Clasificación Internacional C07K 16/20 Nº de solicitud 21861597 Solicitante UNIV NAT CORP EHIME UNIV Inventor/a TSUBOI TAKAFUMI
The present disclosure includes a monoclonal antibody or antibody fragment that binds to an epitope consisting of 5 to 20 consecutive amino acids in the amino acid sequence of SEQ ID NO: 1, and a method of detecting or quantifying an Ripr-derived malaria vaccine antigen comprising contacting a sample with the monoclonal antibody or antibody fragment.

40.20230212254IMMUNE CELLS OVEREXPRESSING CELL SIGNALING REGULATORY FACTOR INTRODUCED FROM OUTSIDE AND USE THEREOF
US - 06.07.2023
Clasificación Internacional C07K 14/725 Nº de solicitud 17904221 Solicitante BEIJING YONGTAI RUIKE BIOTECHNOLOGY COMPANY LTD Inventor/a Hoeon KIM
The present invention relates to an immune cell that are engineered to overexpress cell signaling pathway modulator(s) and a use thereof. As a specific example, an immune cell expressing a fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator(s) performs an immune response by selecting a target cancer cell by a chimeric antigen receptor expressed on a cell membrane. In this case, the cell signaling pathway modulator is overexpressed in the cytoplasm, thereby being capable of regulating the activity of an immune cell. Therefore, the fusion protein comprising a chimeric antigen receptor and cell signaling pathway modulator(s), and the immune cell engineered to overexpress the cell signaling pathway modulator(s) of the present invention can be usefully used in the treatment of cancer.

41.WO/2023/130096CORONAVIRUS VACCINE COMPOSITIONS AND USES THEREOF
WO - 06.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/082665 Solicitante BOOST BIOPHARMA, INC. Inventor/a SCHOMBURG, Fritz
Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein. Also provided are a method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by a coronavirus in a subject which includes administering to the subject the recombinant polypeptide, and a method for inducing an immune response against a coronavirus in a subject, which includes administering to the subject the recombinant polypeptide.

42.WO/2023/130040T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER
WO - 06.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/US2022/082579 Solicitante THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor/a KRISHNA, Sri
Disclosed are methods of treating or preventing cancer in a mammal, the method comprising: (a) isolating T cells from a tumor sample from the mammal, wherein the isolated T cells are one or both of exhausted

and differentiated, and the isolated T cells have antigenic specificity for a tumor-specific antigen expressed by the tumor sample from the mammal, wherein the tumor-specific antigen is a tumor-specific neoantigen or an antigen with a tumor-specific driver mutation; and optionally expanding the numbers of isolated, tumor antigen-specific T cells; and (b) administering to the mammal (i) the isolated T cells of (a) and (ii) a vaccine which specifically stimulates an immune response against the tumor-specific antigen for which the isolated T cells have antigenic specificity.

43.20230210975BACTERIAL IMMUNIZATION USING NANOPARTICLE VACCINE
US - 06.07.2023
Clasificación Internacional A61K 39/09 Nº de solicitud 18008777 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a Roberto ADAMO
Methods of inducing an immunogenic response against a bacterial polysaccharide or oligosaccharide, and constructs and compositions for use in such methods.

44.WO/2023/125976FUSION PROTEIN VACCINE
WO - 06.07.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/144163 Solicitante GUANGZHOU NATIONAL LABORATORY Inventor/a PENG, Hua
A fusion protein, comprising an antigen domain and an immune cell targeting domain.

45.20230212231SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES
US - 06.07.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17927804 Solicitante Institut National de la Santé et de la Recherche Médicale (INSERM) Inventor/a Yves LEVY
The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.

46.20230212243Neoantigenic Epitopes Associated with SF3B1 Mutations
US - 06.07.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17924013 Solicitante Institut Curie Inventor/a Olivier Lantz
The present application relates to a tumor specific neoantigenic peptide, wherein said peptide is encoded by a part of an ORF sequence from a transcript associated with a SF3B1 or a SF3B1-like mutation, comprises at least 8 amino acids and binds at least one MHC molecule with an affinity of less than 500 nM; and is not expressed in normal healthy cells. The present application further relates to vaccine or immunogenic composition, antibodies, T cell receptors, polynucleotides, vectors and immune cells derived thereof as well as their use in therapy of cancer.

47.20230210720SYSTEMS AND METHODS FOR FLUID DELIVERY MANIFOLDS
US - 06.07.2023
Clasificación Internacional A61J 1/06 Nº de solicitud 18181664 Solicitante Koska Family Limited Inventor/a Marc Andrew Koska
A fluid delivery manifold system assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery

assembly generally includes a modular manifold design consisting of separately constructed components cooperatively arranged and coupled to one another. The modular manifold construction allows for rapid manufacturing reconfigurations of one or more components with minimal costs to create new delivery manifold configurations that meet specific needs (i.e., different modes of delivery depending on agent to be delivered, such as subcutaneous, intramuscular, intradermal, intravenous injection, spray, or droplet delivery).

48.WO/2023/128594POLYPEPTIDE FOR DELIVERING ANTIGEN TO IMMUNE CELLS
WO - 06.07.2023
Clasificación Internacional C07K 7/06 Nº de solicitud PCT/KR2022/021480 Solicitante JW CREAGENE INC. Inventor/a JEON, Yoon Jae
The present invention relates to a polypeptide for delivering an antigen to immune cells and, specifically, to: a novel polypeptide including a cell membrane penetrating peptide and a peptide binding to a surface molecule on immune cells; a fusion polypeptide in which an antigen is coupled to the polypeptide; a nucleic acid coding for the polypeptide or the fusion polypeptide; an immune cell immunized with the fusion polypeptide or the nucleic acid coding therefor; and an immunotherapeutic agent, antitumor or anticancer vaccine, and a composition for treating a tumor or cancer, each comprising the immune cell.

49.WO/2023/123959ALUMINUM-MANGANESE COMPOSITE NANOCRYSTAL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 06.07.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/102747 Solicitante THE GBA NATIONAL INSTITUTE FOR NANOTECHNOLOGY INNOVATION Inventor/a CHEN, Chunying
An aluminum-manganese composite nanocrystal, and a preparation method therefor and the use thereof. The method for preparing the aluminum-manganese composite nanocrystal comprises: step 1, mixing an aluminum salt solution, a manganese salt solution and an anionic adjuvant solution to obtain a mixture, and adjusting the pH value of the mixture to 5.5-8.5; and step 2, heating the mixture for a reaction, and washing the obtained solid reactant to obtain the aluminum-manganese composite nanocrystal. According to the aluminum-manganese composite nanocrystal prepared using the preparation method and the use thereof in the preparation of a vaccine adjuvant, a pharmaceutical composition, a drug delivery carrier or an immunogenic composition, the technical problem that an existing aluminum adjuvant cannot activate humoral immunity and cell immunity at the same time can be effectively solved.

50.20230212244NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
US - 06.07.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 18063418 Solicitante Immatics Biotechnologies GmbH Inventor/a Oliver SCHOOR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

51.4205762VERBESSERTER DNA-IMPFSTOFF FÜR SARS-COV-2
EP - 05.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21875809 Solicitante UNIV OSAKA Inventor/a NAKAGAMI HIRONORI

Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.

52.20230213518RAPID VERIFICATION OF VIRUS PARTICLE PRODUCTION FOR A PERSONALIZED VACCINE
US - 06.07.2023
Clasificación Internacional G01N 33/569 Nº de solicitud 18067508 Solicitante NANTCELL, INC. Inventor/a Adrian E. Rice
Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES